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Summary 
 
In this thesis, the properties and potential application fields of saccharide-based 
block copolymers are explored. 
The anionic polysaccharide heparin was coupled to hydrophobic blocks – 
poly(dimethyl siloxane) (PDMS) and poly (ethyl ethylene) (PEE) – using different 
synthetic methods, and investigated in terms of self-assembly behavior and 
insertion into polymeric membranes. We studied whether heparin’s intrinsic 
anticoagulant activity is persistent upon chemical transformation and insertion 
into polymer membranes. We observed that coupling does not influence the 
anticoagulant activity, whereas methods involving degradation of heparin led to 
an almost complete loss of activity. 
 
We also coupled heparin to the hydrophilic polymer poly(ehtylene glycol) (PEG), 
which produced a bis-hydrophilic block copolymer. Self-assembly of this anionic 
material in association with gadolinium cations was investigated by transmission 
electron microscopy. Electron paramagnetic resonance (EPR) spectroscopy 
provided more details about the polymer – metal interactions. The choice of 
gadolinium was justified by the fact that it has good contrast properties for 
medical imaging. In combination with the polymer, toxicity of gadolinium could be 
decreased. In addition, its relaxivity was enhanced. This way we obtained a new 
type of contrast agent. 
MRI experiments proved that the relaxivity of the polymer-bound gadolinium was 
significantly higher than of unbound gadolinium and of commercially available 
gadolinium-based contrast agents. To further lower toxicity of gadolinium, we 
added phosphate to form small insoluble GdPO4 particles, which were in fact 
stabilized in solution by polymer aggregates. Their contrast properties only 
slightly decreased compared to polymer-bound gadolinium ions. 
 
Apart from synthetic blocks, we also combined sugar units with peptides. Firstly, 
we established new synthetic routes towards such biohybrids, using 
monosaccharides and a short peptide (named TRUNK). The coupling of D-
glucuronic acid to the TRUNK was successfully achieved on solid phase. The 
resulting glycopeptide was investigated in terms of its self-assembly behavior. 
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This thesis is structured in eight parts. The first chapter is an introduction, 
focusing on amphiphiles and copolymers based on biological blocks. Chapter two 
includes the motivation and the concept of this work. In the third chapter, the 
results are described and discussed in detail. This chapter is divided into four 
main sections, dealing with heparin-based copolymers with amphiphilic as well as 
bis-hydrophilic properties. The latter was explored as a matrix for MRI contrast 
agents. Additionally, the synthesis and self-assembly behavior of materials 
combining carbohydrate and peptide blocks are discussed. 
In chapters four and five we draw the conclusions and present the outlook for 
prospective experiments. The experimental conditions are given in chapter six, 
as well as descriptions of methods and equipment. The thesis finalizes with the 
references in chapter seven and an appendix including a historical outline of 
heparin in chapter eight. 
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1 INTRODUCTION 
 
1.1 Amphiphilic self-assembly 
 
Amphiphiles play a fundamental role in biology. Essential fatty acids are used in 
the human body as energy resources and are involved in the prevention and 
treatment of coronary artery disease, hypertension, diabetes and arthritis, other 
inflammatory and autoimmune disorders and cancer1. Another prominent class of 
amphiphiles is represented by lipids, particularly phospholipids, the main 
component of biological membranes. Cholesterol and glycolipids are also part of 
those structures, responsible for the membranes’ physical and biological 
properties. Cholesterol is present in mammalian cell membranes, forming 
microdomains, commonly referred to as “rafts” that contain high concentrations of 
membrane proteins2. Glycolipids serve four general functions in membranes: 
stabilization, shape determination, recognition, and ion binding3.  
The common intrinsic feature of amphiphiles (from the Greek amphis: both; 
philia: love, friendship) is the covalent linkage of parts with different polarities, 
which hence favor different solvents but cannot separate at the macroscopic 
scale. Parts which favor unpolar solvents are called hydrophobic or lipophilic and 
conversely those parts which are well soluble in aqueous media are called 
hydrophilic or lipophobic. 
When exposed to a solvent, amphiphiles can self-assemble spontaneously and 
reversibly into ordered structures as a result of opposing interaction preferences 
of the chemically different parts. Self-assembly in the case of amphiphiles is 
based on non-covalent, mainly hydrophobic interactions and is commonly defined 
as lyotropic behavior. The Greek root (“lyo-“ = solvent, “-tropic” = induced by) 
hints that the phase diagram is typically based on the molecule and solvent 
properties and on the concentration4. Considering thermodynamics, the drive for 
amphiphiles to organize in aqueous media derives from opposing preferences of 
the blocks with different polarities5. Avoiding contact between the hydrophobic 
chain and water molecules by segregation leads to entropy gain, thus decreasing 
the total free energy of the system. 
The degree of repulsion, block length, concentration, and solvent selectivity 
determine the morphology of the self-assembly, which ranges from lamellae to 
micelles, vesicles, and other more complex shapes. The concept of the critical 
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packing parameter (Pc) was introduced as a model to predict the morphology of 
amphiphiles self-assembling into superstructures6: 
 
(Pc) = V/a0L 
 
V :  hydrophobic chain volume 
L :  length of the hydrophobic chain 
a0:  area occupied by the hydrophilic group 
 
For small amphiphilic molecules with a Pc < 0.5, highly curved aggregates such 
as spherical and cylindrical micelles are predominant, while for 0.5 > Pc > 1 
smaller curvature is favored. When Pc is close to 1, planar bilayers are formed. 
The same principle is true for amphiphilic macromolecules, both biological and 
synthetic polymers, but additional factors such as polydispersity and flexibility 
play a role. 
 
1.2 Polymers 
 
At the beginning of the 20th century, the successful quest for surrogates for ivory, 
natural fibers, and rubber emerged parallel with the process of understanding the 
structural features of polymers. In 1907, Baekeland was the first to present a fully 
synthetic polymer – Bakelite – with excellent electrical insulating features. By this 
time, the molecular architecture of polymers was still unknown and it was 
believed that micellar self-assembly of molecules accounted for polymer 
properties. In 1920, when Hermann Staudinger (1881-1965) discovered that 
polymers consist of covalently bound building blocks7, he already presumed the 
immense potential arising from the variety of polymeric substances and opened 
the door for future development of functional and structural high-tech materials8.  
The term polymer describes a molecule that consists of repeating low molecular 
mass structural units (monomers). Addition or subtraction of a few monomers to 
or from a polymer has a negligible effect on its chemical and physical properties. 
Copolymers represent a special class of polymers; they are built by at least two 
different sorts of monomer units (co-monomers). Mainly, physical properties of 
copolymers depend not only on the chemical nature of the monomers but also on 
their arrangement within a macromolecule. They are classified by means of their 
structural composition: 
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Statistical copolymers are built up by statistically distributed co-monomers, as for 
the example of a statistical copolymer with two units A and B: 
 
AABBAAABABAABBABAABBBABAABAAABA 
 
Alternating copolymers consist of a regularly repeating pattern of monomer units: 
 
ABABABABABABABABABABABABABABABA 
 
Periodic copolymers, similar to alternating copolymers also are constructed by 
regular repeating units, but sequences instead of single monomers: 
 
AABBBAABBBAABBBAABBBAABBBAABBB 
 
Graft copolymers represent a class of branched polymers with side chains 
grafted to the backbone: 
 
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
 B  B     B 
 B  B     B 
 B  B     B 
 B  B     B 
 
Linear block copolymers are formed by a linkage of chains consisting of one 
monomer type: 
AAAAAAAAAAAAAAAABBBBBBBBBBBBBB 
 
Just like lipids, amphiphlic block copolymers self-assemble into superstructures. 
When exposed to water, the hydrophobic part is protected from the aqueous 
environment. All forces leading to self-assembly in polymer systems are similar to 
those of low molecular weight amphiphiles, although the resulting morphology is 
predicted by the weight fraction of of the hydrophilic block, unlike for small 
molecules, where Pc is applied. At constant concentration in solution, increasing 
the length of the hydrophobic block at constant hydrophilic block leads to a 
transition from spherical to worm-like micelles and finally to vesicular 
structures9,10,11 (Figure 1). 
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Figure 1: Three microstructures - vesicles, cylinders, and spheres - can be observed for 
aqueous dispersions of PB-PEO diblock copolymers by cryogenic transmission electron 
microscopy. The existence of these microstructures depends on the weight fraction of PEO11. 
 
The self-assembly process is driven by an unfavorable mixing enthalpy and a 
small mixing entropy, while covalent bonds between the blocks prevent 
macrophase separation12. However, not only thermodynamic control, but also 
kinetics of chain rearrangements can influence the phase behavior of amphiphilic 
systems. The resulting kinetically trapped structures are not perforce at the 
absolute free energy minimum state. 
The first polymeric vesicles reported13, 14 were from diblock dendrimers and 
copolymers made of poly(styrene) as hydrophobic block. Due to the high glass 
transition temperature (Tg) of poly(styrene), a higher energy barrier has to be 
overcome to achieve self-assembly and therefore the use of mixed solvents such 
as DMF or toluene in water is needed for the formation of colloidal structures. 
Hydrophobic blocks with lower Tg can accelerate the membrane formation by 
lowering the activation energy and thus make the use for cosolvents needless as 
for example with poly(butadiene), poly(ethyl ethylene), poly(dimethyl siloxane), 
poly(propylene sulfide), poly(butylene oxide), poly(propylene oxide). 
Several amphiphilic multiblock copolymer architectures were synthesized and 
explored in terms of their self-assembly behavior. The control over other physical 
and chemical properties of self-assembled aggregates such as permeability or 
responsiveness was achieved by the right choice of building blocks. 
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1.3 Functional polymer membranes 
 
Different approaches were used to tune the properties of amphiphilic block 
copolymers and polymer membranes for applications in biosciences as varied as 
diagnostics, drug delivery and sensor technology15. 
In contrary to lipids, polymer chemistry allows for various chemical modifications 
to introduce functionality and make polymers responsive to environmental stimuli. 
Unsaturation of the hydrophobic block16 or introduction of a methacrylate end-
functionality17 were used to crosslink and thus stabilize membranes in water. 
Many research groups investigated vesicle forming properties of block 
copolymers that can be degraded upon a change on pH by hydrolysis18,19 or by 
exposure to oxidants20, 21. Degradability resulting in vesicle destabilization is an 
attractive feature for controlled release of e.g. drugs. 
Another example of degradable superstructures are azobenzene-based block 
copolymers that were reported to form light-responsive vesicles, which reversibly 
disintegrate when exposed to UV light (360 nm) due to conformational changes 
in the azobenzene and rebuild upon illumination with visible light (440 nm)22. 
Insertion of membrane proteins provides additional functionalization possibilities, 
where the natural properties of the proteins are retained in synthetic membranes. 
Particularly, membranes formed by poly(methyloxazoline)-poly(dimethyl 
siloxane)-poly(methyl oxazoline) (PMOXA-PDMS-PMOXA) triblock copolymers 
were used for such a purpose. The bacterial porin OmpF proved to be 
consistently active in artificial membranes23, allowing passive diffusion of small 
molecules up to 400 Da across the membrane. The enzyme β-lactamase was 
encapsulated into polymeric vesicles and ampicillin was added to the vesicle 
solution. Ampicillin can be hydrolyzed by β-lactamase to ampicillinoic acid after it 
reached the inside of the vesicle through the channels. Ampicillinoic acid is able 
to reduce iodine to iodide. Therefore, the activity of the enzyme could be 
monitored by iodometry (Figure 2). 
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Figure 2: Vesicular nanoreactor by insertion of OmpF into a polymeric membrane. β-lactamase 
hydrolyzes amphicillin to ampicillinoic acid, that can be detected iodometrically24. 
 
Other attempts followed to prove functionality of channel-forming membrane 
proteins in artificial membranes using proteins with more specific permeabilities: 
The bacterial channel protein LamB, which serves also as receptor for λ phage to 
release its DNA, was inserted into polymeric membranes for virus-assisted 
loading of polymer nanocontainers25. The incorporation and release was 
monitored using the fluorescent dye YO-PRO-1, a label for the viral DNA.  
Insertion of the specific water channel Aquaporin Z26 into polymer membranes 
led to increased water permeability of the membranes, by orders of magnitude. 
Furthermore, the selectivity of the Aquaporin Z-polymer membrane for water over 
small solutes such as salt, glucose, urea and glycerol was demonstrated. 
Polymeric vesicles have been used as a model for biomimetic mineralization 
such as what nature applies for production of inorganic composites like bones or 
teeth. Insertion of calcium transporting ionophores was achieved for controlled 
precipitation of calcium phosphate in giant polymer vesicles27. For medical 
application of polymeric vesicles, not only the control over permeability, but also 
programmability towards specific targets is a great challenge of biomaterial 
science. Vesicles from biotinylated PMOXA-PDMS-PMOXA block copolymers 
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attached to biotinylated ligands using streptavidin as coupling agent, thus 
demonstrating the applicability of polymer nanocontainers as injectable cell-
targeting vehicles. The nanocontainers bound to the cell surface were rapidly 
taken up without observable cytotoxic effect28.  
A more direct approach to introduce biofunctionality is to tailor the polymer’s 
properties at the stage of molecular engineering, one possibility being the use of 
biological building blocks, such as sugars and peptides. This way, new properties 
of the resulting materials can be expected, and improved biocompatibility may 
facilitate applications such as drug delivery or medical imaging. In the following 
sections, such bio-blocks will be discussed in more detail. 
 
1.4 Biohybrid amphiphiles (I): Sugars as building blocks 
 
In nature, carbohydrates represent a main building class of living matter, where 
they are usually associated to proteins, lipids (as glycolipids), making up a part of 
biological lipid membranes and are also parts of DNA and RNA29. 
Exploring functional carbohydrates as building blocks of amphiphilic block 
copolymers opens the possibility to investigate their biofunctionality as 
membrane-forming material and to design membranes that can interact 
specifically with proteins.  
Sugar-based surfactants, such as Sorbitan esters, sucrose esters and alkyl 
polyglycosides are well established in industrial applications such as leather and 
textile auxiliaries, emulsifiers for food, cosmetics, dishwashing and detergent 
applications. For household applications, alkyl polyglycosides feature very good 
performance and mildness and are completely based on renewable resources; 
therefore they are the most successful sugar-based surfactants nowadays30. 
Out of all classes of sugars known, many are only used for very specific 
applications, depending on their activity spectrum determined by nature. As an 
example, a major component of the mammalian extracellular matrix is 
proteoglycans, proteins covalently linked to glycosaminoglycans (GAGs), which 
can interact with different proteins or enzymes to regulate their activity31. 
GAGs (or mucopolysaccharides) are linear polysaccharides consisting of partly 
sulfated alternating glucosamine and uronic acid units. The most prevalent GAGs 
are chondroitin sulfate, dermatan sulfate, keratin sulfate, hyaluronan, heparan 
sulfate and heparin with the highest negative charge density of any known 
biological molecule. The high charge density, its anticoagulant activity and ability 
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to interact with fibroblast growth factors make heparin an interesting candidate as 
bioactive building block for hybrid molecules such as glycopolymers. 
Several attempts have been made to bind heparin covalently32 or non-
covalently33 to solid supports in order to prepare blood compatible surfaces, 
chromatographic gels for affinity chromatography and to study heparin-protein 
interactions. Heparin-coated albumin microspheres were used as ion-exchanging 
drug delivery systems with controlled release34. Porous poly(D,L-lactic-co-glycolic 
acid) (PLGA) microspheres were coated with heparin for sustained release of 
basic fibroblast growth factor (bFGF) to induce angiogenesis35. 
The methods to covalently couple heparin (Figure 3) include the binding to 
functional groups, as for example peptide binding at the carboxylate present at 
every uronic acid moiety. The main drawback here is the unpredictable amount of 
coupled material. Although Bergman et al.36 claim to be able to control the 
coupling ratio by varying the quantity of the coupling reagent, in the case of 
amphiphiles the determination by NMR fails due to the lack of a good solvent. 
 
a) 
Polymer blocks
Heparin
 
b)  
 
 
Polymer blockHeparin
Figure 3: a) Polymer blocks grafted to heparin via peptide binding on the carboxylate functional 
group. b) Polymer blocks bound linearly after end functionalization of heparin 
 
On the other hand, end-group functionalization of heparin allows highly 
predictable block proportions but includes degradation and therefore loss of 
heparin’s anticoagulant activity. The purpose and potential application of the 
resulting material have to be well considered before choosing the coupling 
method.  
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1.4.1 Heparin 
 
Structure and biological activity 
 
Heparin is a linear polysaccharide composed of repeating units of iduronic acid, 
some containing an O-sulfate group at the C2 position and D-glucosamine, 
usually N-sulfated with an additional O-sulfate group at C637. Heparin exists 
primarily as an extended helical structure and is not known to fold to any tertiary 
structure. The specific interactions of heparin with proteins depend on the 
exposure of the sulfo- and carboxyl groups on the surface. The conformational 
flexibility of L-iduronic acid is probably responsible for heparin’s wide range of 
interaction partners. 
Heparin has a very broad molecular mass distribution; however, the 
anticoagulant activity strongly depends on the chain length. The molecular weight 
(MW) of unfractionated heparin (UFH) ranges between 4000-40’000 Da, 15’000 
Da being the most frequent MW. Low molecular weight heparin (LMWH) can be 
obtained by ultrafiltration or by cracking and has a less heterogeneous MW 
distribution, ranging between 4000 and 6000 Da. 
The numerous negative charges are important for different reasons. They are key 
for the complex building with antithrombin III (ATIII) (Figure 4), which is the basis 
of heparin’s anticoagulant activity38.  
 
 
 
Figure 4: Heparin-ATIII complex38 
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They are also important for the interactions with the inactivator protamine, a 
polycationic protein. To be able to interact with ATIII and thus be biologically 
active, heparin needs a minimum of a particular pentasaccharide as binding 
site39,40 (Figure 5) 
 
 
 
Figure 5: Active pentasaccharide moiety of heparin 
 
Only ca. 22% of unfractionated heparin and ca. 16% of low molecular weight 
heparin consist of this bioactive pentasaccharide sequence, the remaining part 
consists also of alternating glucosamine-iduronic acid units, however, sulfate 
groups are distributed randomly. 
The development of low molecular weight heparin began in the 1980s. To 
provide better regulation of blood coagulation a more specific compound than 
unfractionated heparin (UFH) had to be found, which might overcome the major 
pharmacokinetic, biophysical and biological limitations. Apart from complications 
common to all coagulants, such as bleeding, UFH can cause heparin-induced 
thrombocytopenia (HIT) and osteoporosis. Various research groups found out 
that chemical or enzymatic fractionation of heparin led to much more specific 
inhibition of factor Xa41,42,43,44. LMWH was introduced as new effective and 
improved antithrombotic agent with a chain length ranging from 4000 to 6000 Da. 
Major advantages of LMWH over UFH are its improved pharmacokinetic and 
biological properties resulting in longer biological half-lives and its enhanced 
subcutaneous bioavailability. As a result, LMWH can be administered in 
subcutaneous injections each day, permitting its clinical use on an out-patient 
basis. This has reduced the hospitalization costs normally associated with the 
intravenous use of heparin45,46.  
Recently, a scandal outraged the world concerning heparin products. Despite the 
awareness of all benefits of LMWH, UFH is still produced and used in medicine 
as cheaper anticoagulant alternative. Impurities in some UFH batches produced 
from porcine intestinal mucosa led to at least 19 death cases in the US in spring 
2008. Allergic shocks of patients taking the same UFH medicament have been 
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reported in Europe. Production of LMWH includes more purification steps, thus 
such dramatic adverse effects from impurities could be avoided. 
For a detailed historical outline of heparin development, see annex chapter 8.3. 
 
Blood clotting 
 
If an organism is injured, it needs the ability to control blood clotting. This means 
that there must be a regulatory mechanism that stops blood flow, starts clot 
formation, and finally terminates the process. The first step after injury is 
constriction of blood vessels, preventing massive bleeding. Next, platelets 
become activated by thrombin and aggregate at the site of injury, forming a 
temporary, loose platelet plug, and further release proteins important for the 
coagulation cascade. The last step of the cascade is the formation of a fibrin 
mesh which stabilizes the platelets resulting in the actual clot. 
There are two pathways in the coagulation cascade (Figure 6), the intrinsic and 
the extrinsic one, which come together at the activation point of factor X to Xa47. 
The clot growth is controlled by specific inhibitors, the most important of them 
being antithrombin III (ATIII), which inhibits factor Xa among others.  
The activity of ATIII is potentiated in the presence of heparin by the following 
means: heparin binds to a specific site on antithrombin III, altering the protein 
conformation, and the new conformation has a higher affinity to factor Xa. Thus 
blood coagulation is prevented48 . 
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Figure 6: The intrinsic and the extrinsic pathway of the blood clotting cascade 
 
Due to its biological properties and high density of negative charges, heparin can 
be exploited in studies of self-assembly, bioactivity and medical applications of 
materials based on this particular biological block.  
1.5 Magnetic resonance imaging (MRI) and contrast agents 
 
The vast building block diversity and stability of hybrid polymeric materials 
provides the opportunity to establish them in a wide range of applications, such 
as drug delivery systems, diagnostics and imaging. However, to be suitable for 
life science, biocompatibility is an essential feature.  
Good biotolerance can be achieved by covering a surface with PEG to obtain a 
steric protection against opsonization and macrophage uptake and thus prolong 
the vascular retention time49. When PEG is covalently attached to a negatively 
charged polymer, for example an anionic saccharide, the block-copolymer can 
interact with a cation such as Gd3+ and form an aggregate. 
Gadolinium is a well known positive contrast agent for MRI, that affects the 
longitudinal relaxivity of protons. They are associated to the relaxation time T1, 
which is characterized by the longitudinal return of the magnetization to its 
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maximum. (Negative contrast agents affect T2, the time needed to lose the 
transverse magnetization.)  
MRI is an imaging technique that does not involve ionizing radiations and has 
been increasingly used over the years for its safety for the patients and its ability 
to discriminate between different tissues and between healthy and pathological 
structures. 
MR images have excellent contrast, mainly because the magnetic relaxation time 
constants T1 and T2 differ markedly between tissues (Figure 7). 
 
 
Figure 7: Example of an MRI section of my upper body without contrast agent. Areas with a high 
proton density like blood vessels and some organs are bright. 
 
Nevertheless, certain diseases leave T1 and T2 unchanged and, as a result, allow 
no change in image intensity. Contrast agents facilitate the detection of certain 
abnormalities that would have otherwise the same intensity as surrounding 
tissues, and also help resolve ambiguity between possible diagnoses. 
The parameter that describes the performance of an MRI contrast agent is the 
relaxivity, which is the ratio between the change in relaxation times of the imaged 
tissue and the concentration of the contrast agent in the tissue itself, according to 
the following formula: 
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T1/2     =  T1 or T2 values of the tissue with contrast agent  
T1/2,0   =  original T1 and T2 values of the tissue  
r1/2      = relaxivity values 
C       =  concentration 
 
Contrast agents (CA’s) affect both - T1 and T2 - values, and for gadolinium-based 
compounds, r1 and r2 values are normally similar. When the value of r2 is less 
than twice the value of r1, the CA can be used as a positive enhancer, meaning 
that the pixel intensity is higher where the contrast agent is localized; otherwise, it 
can be used as a negative enhancement CA, which reduces the image intensity 
in the tissue. 
Positive enhancers are generally preferred by clinicians, because high intensity 
spots are more visible on images and less mistakable for artifacts.  
Gadolinium is a positive CA but as a plain ion it is toxic due to its interaction with 
phosphate in the cells and its accumulation in bone tissue. Therefore gadolinium 
ions have to be embedded into a matrix that meets the biocompatibility 
requirements. Moreover, coating results in contrast gain because of the retention 
of water molecules in close proximity to the gadolinium. The reduction of the 
translational and rotational mobility induces also an enhancement of the 
relaxivity. Many gadolinium-embedding CA products are already available on the 
market, such as MultiHance and ProHance® (Bracco) Magnevist® (Bayer), 
Omniscan® (GE Healthcare) and OptiMARK® (Covidien). However, there is still a 
wide range of research going on to further increase the relaxivity and thereby 
reduce the amount of required gadolinium. The majority of the proposed matrix 
materials are based on chelators such as diethylene triamine pentaacetic acid 
(DTPA) or the kinetically more stable tetraaza cyclododecane tetraacetic acid 
(DOTA)50, more recent research focuses on dextran stabilized particles51 or 
liposomes incorporating lipophilic gadolinium complexes such as Gd-DTPA52. 
Stabilization of gadolinium with anionic polysaccharides such as heparin has 
been patented53 but not further investigated: no PEGylation of the polysaccharide 
and no addition of phosphate was explored. 
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1.6 Biohybrid amphiphiles (II): Peptides as building blocks 
 
The countless possibilities towards the design of new amphiphilic compounds 
with a biological block are not limited by their linkage to synthetic units, but also 
include combinations among each other.  
Not only the monomer sequence, but also specific intramolecular folding motifs 
and intermolecular interactions can control formation of superstructures54. 
Controllable specific interaction is a desirable feature of membrane constituents. 
Peptides and proteins organize into characteristic secondary and tertiary 
structure to be able to fulfill their biological tasks. This process involves formation 
of disulfide bonds and weaker nonbonding interactions such as Van der Waals-
forces, π-π interactions and hydrogen bonds. Such specific attraction forces as 
part of the membrane formation process is an attractive approach towards 
precisely built superstructures55.  
For example, amphiphilic peptide sequences deriving from the antibiotic 
gramicidin were synthesized as model systems to investigate how self-assembly 
can depend on individual building blocks55, 56.  
Gramicidin is a short antibacterial peptide deriving from Bacillus brevis that 
consists of 15 amino acids57: 
   
formyl-L-X-G-A-dL-A-dV-V-dV-W-dL-W-dL-W-dL-W-ethanolamine 
 
The sequence is entirely hydrophobic and exhibits a β-sheet-like pattern of 
hydrogen bonds. The backbone folds into a β6.3-helix, a secondary structure 
formed by the association of parallel beta strands in a helical pattern. The 
superscript indicates the number of units per turn in the helix. Gramicidin inserts 
into membranes to form channels specific for the transport of monovalent cations 
across membranes58. The high affinity of gramicidin channels to each other 
suggests this peptide a suitable candidate as hydrophobic block for self-
assembling amphiphiles. 
In fact, Kimura et al were among the first ones to report vesicular self-assembly 
of a gramicidin-polymer (PEG) conjugate56. 
A purely peptidic derivative of gramicidin and its reduced sequence, the seven C-
terminal amino acids, was synthesized by Dittrich et al by N-terminal addition of 
oligo-lysine55. Dialysis of the peptide solubilized in ethanol led to the formation of 
rigid and monodisperse spherical structures, predominantly micelles. The 
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hydrophilic lysine with a pKa of 10.2 can act as molecular switch. Removal of the 
charges by increasing the pH results in immediate but reversible precipitation59.  
The properties of this fully peptidic amphiphile can be changed in terms of 
functionality by amino acid point mutations or insertion of functional groups other 
than amino acids. 
Combination of peptides with saccharides leads to glycopeptides. Not only the 
need for homogenous samples (single glycoforms) for the better understanding 
of glycoprotein formation and function, but also their exploitation in terms of self-
assembly and applications has resulted in great effort in the synthesis 
development of glycopolymers over the past 15 years60,61-64. 
The vast majority of natural glycopeptide synthesis is based on O-glycosidic 
linkage via the hydroxyl groups of serine and threonine or N-glycosidically via the 
amide side chain of asparagines, resulting in a peptidic bond. Many synthetic 
routes have been exploited to achieve chemical or enzymatic glycosilation, as 
reviewed recently65. 
The need to synthesize glycopeptides in large quantities is not only based on the 
research need to understand how glycosilation affects the function and activity of 
proteins, but also on the current investigations for new vaccines. Cancer cells 
and viruses tend to express selective carbohydrate motifs in the form of 
glycoproteins or glycolipids. Utilization of those carbohydrates in a glycopeptide-
based vaccine could potentially trigger immune recognition, generating a 
protective response against the disease. Since the isolation of carbohydrate 
antigens from natural sources is difficult and yields mostly minimal quantities, it is 
virtually impossible to obtain homogeneous starting materials for medical use. 
Therefore the purity and availability problem falls to organic chemists to be 
solved66.  
Although many elegant and rapid preparation methods for glycopeptides have 
been found, there is still a need to explore ways that require minimal protection 
and one-pot glycosylations towards complex constructs that can be used in 
clinical settings. 
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2 MOTIVATION AND CONCEPT 
2.1 Motivation 
 
Heparin is a hydrophilic linear polysaccharide, with high density of negative 
charges. Its main biological role is - among others - controlling blood coagulation, 
and therefore it finds medical applications as an anticoagulant agent. 
When combined to different synthetic polymers or natural blocks like peptides, 
interesting material properties and aggregation behavior could be foreseen, due 
to amphiphilic or bis-hydrophilic self-assembly. In particular, the question whether 
heparin would retain its biological activity depending on the block copolymer 
synthesis and the self-assembly process was important for perspective 
applications. 
Materials combining saccharide and peptide blocks would have novel 
characteristics, since the peptide’s intrinsic secondary structure and the features 
of short amphiphilic peptides promise a well defined aggregation behavior. To 
explore feasibility and adaptability of such bio-inspired amphiphiles, it was 
interesting to establish new synthesis pathways to produce glycopeptides 
consisting of a gramicidin-derived sequence linked to a monosaccharide and to 
study aggregation properties of such hybrid materials under different 
experimental conditions. 
The primary motivation of this work was to study the aggregation properties and 
potential applications of glycopolymers and glycopeptides, especially hybrid 
materials consisting of heparin or its monosaccharide units. 
Additionally, given the heparin’s charges, we assumed electrostatic interactions 
of heparin-PEG with metal ions and thus the formation of metal-encapsulating 
superstructures. A further goal of this study was the development a new type of 
contrast agent for medical imaging using gadolinium. 
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2.2 Concept 
 
Carbohydrates such as heparin are promising candidates for the exploitation of 
the behavior of hybrid materials. Heparin as hydrophilic part of an amphiphilic 
block-copolymer may be used to functionalize the surface of colloidal 
nanoparticles such as vesicles or micelles. Key to any biomedical application is 
the retention of heparin’s biological activity. 
We will synthesize amphiphilic copolymers composed of a hydrophobic 
poly(dimethyl-siloxane) (PDMS) block and low molecular weight heparin (LMWH) 
as the hydrophilic one. Different approaches can be implemented to characterize 
the properties of heparin-PDMS, i.e. binding of heparin to protamine67 used in 
medicine as heparin inhibitor and the anticoagulant activity of heparin-based 
materials. 
As an example of a biomedical application for glycopolymers, a new type of MRI 
contrast agent using stabilized GdPO4 can be introduced. In order to obtain a 
good CA it is necessary to decrease the mobility of the system and in this respect 
we propose to use heparin-PEG block copolymers which will trap the gadolinium 
ions inside their core. 
This bis-hydrophilic material consisting of heparin and the non-toxic hydrophilic 
block PEG can be applied as matrix for gadolinium phosphate particles. This 
copolymer is a promising candidate due to its hydrophilic character which 
ensures retention of water molecules in proximity of the paramagnetic core giving 
a high relaxivity. The ensuing addition of phosphate results in formation of small 
and stable gadolinium-phosphate particles, which reduces the toxicity of 
gadolinium. 
 
Another class of block copolymers containing bio blocks are glycopeptides: they 
consist of a peptide block and a sugar block. Peptides open a new interesting 
class of tectons for amphiphilic block copolymers to be investigated in terms of 
synthesis and self-assembly behavior.  
The idea of this project is to couple the hydrophobic oligopeptide tryptophane-(D-
leucine-tryptophane)3 to the hydrophilic monosaccharide D-glucuronic acid by 
Fmoc-solid phase, resulting in an amphiphilic glycopeptide (W(DL-W)3-GluAc). 
Furthermore, glucosamine could be coupled to the same peptide, but due to its 
amino functionality, the simple SPPS strategy is inapplicable. Therefore new 
strategies, such as a “backwards” coupling method – where the peptide is 
detached from the solid phase – in solution have to be explored. A coupling on 
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solid phase is conceivable by reductive amination. The already gained insights of 
purely peptidic materials based on gramicidin and its derivatives can be 
expanded by the insertion of a new class of molecules and investigated in terms 
of their applicability for e.g. vaccines. DLS, CLSM and TEM are promising 
methods to explore the self-assembly behavior of such hybrid materials in 
different solvents. 
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3 RESULTS 
3.1 Heparin-PDMS 
 
We applied various synthesis strategies to obtain heparin-PDMS block 
copolymers. The first attempt included nitrous acid degradation of heparin to 
obtain aldehyde end-functionalization, which, upon reductive amination was 
coupled to an amino end-functionalized PDMS-block via Schiff’s base. Another 
similar synthesis pathway is iodine oxidation of heparin which results in the 
formation of a lacton end-functionality, which then can also be coupled to an 
amino end-functionalized PDMS by amide bond. 
A different strategy without degradation of heparin is based on DCC/DMAP 
coupling of amino end-functionalized blocks to the carboxylate groups of heparin. 
Using DCC/DMAP coupling, we obtain better yields through a one-pot reaction; 
nevertheless, quantification of the PDMS bound to heparin turns out to be a 
major difficulty.  
 
3.1.1 Heparin coupled to PDMS by nitrous acid degradation followed by reductive 
amination  
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Figure 8: Synthesis pathway of nitrous acid degradation followed by reductive amination 
 
The nitrous acid degradation of heparin seemed to be a reliable way to obtain 
reactive heparin with a desired end-functionality68. We coupled the functionalized 
heparin to a bi-funcional PDMS block by reductive amination and expected it to 
result in an ABA-triblock-copolymer.  
FT-IR spectroscopy revealed the appearance of an aldehyde group at 1738 cm-1, 
which means, that the end-functionalization took place. After the coupling step, 
the aldehyde band disappeared, showing, that the reduction of the aldehyde 
group and thus the coupling worked. 
After washing the polymer with hexane, the product was dissolved in water, 
resulting in a turbid, slightly opalescent solution. This fact and the result from IR 
spectroscopy strongly indicate the formation of a covalent binding between 
heparin and PDMS.  
To investigate, if the resulted amphiphiles are able to self-assemble in water, an 
aqueous solution of the polymer was dried on the rotary evaporator and 
redissolved in water. This rather unconventional variation of the film-rehydration 
method involves dissolution in water to form a thin film by evaporation, because 
the copolymer is insoluble in any other solvent. After extruding the turbid solution 
6 times through a 0.2 µm Millipore filter, TEM images were taken. We observed 
spherical aggregates(Figure 9), but they could not be reproduced.  
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Figure 9: TEM images of heparin-PDMS aggregates. 
 
NMR was performed in a 1:1 mixture of D2O and acetone-D6. The quantification 
was done by comparing the integral of the anomeric protons of the iduronate or 
the glucosamine as described in chapter 6.2.7. Those peaks were chosen, 
because the others overlap and are difficult to quantify. We assumed that a 
heparin molecule with a MW of 5000 Da is composed of approximately 20 
repeating sugar units, which sum up from ten iduronate and ten glucosamine 
saccharides. Comparing the integrals with the ones of the coupled block could 
tell us the coupling ratio. However, PDMS is very poorly soluble in acetone, 
hence no quantification could be made, even though a peak at 0 ppm appeared 
and suggested that the reaction took place.  
Gel electrophoresis revealed no difference between the educt and the product 
runtime. It can be hypothesized, that the stain toluidine blue is not able to interact 
with the degraded heparin due to changed chain length and charges. 
The formation of an ABA triblock-copolymer could not be supported by NMR data 
or gel electrophoresis, however, a covalent binding can be presumed from the 
change in solubility and IR data. Very low yields and products which are very 
difficult to characterize by common analysis methods due to the intrinsic 
incompatible solubilities of the two building blocks, led to a provisional 
abandonment of this method.  
We explored other methods to link heparin to polymer blocks. Formation of a 
lactone using iodine is another method to achieve end-functional coupling of 
heparin. 
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3.1.2 Heparin coupled to PDMS by iodine method  
 
 
Figure 10: Synthesis pathway of lactone end-functionalization of heparin by iodine method 
 
We attempted a second method reported by Matsuda et al.69 which results in an 
end-functionalization of heparin but does not involve its degradation. Heparin 
gets oxidized by iodine, leading to a lactone end-functionality, which can be 
coupled to an amine-functionalized hydrophobic block by an amide bond. This 
strategy resulted in extremely low yields, though, and the characterization with 
NMR resulted in the same unsatisfactory quantification due to poor solubility of 
PDMS in acetone as in the method described in chapter 3.1.1. Heparin is soluble 
in water, poorly in formamide, but in no other solvent. PDMS is moderately 
soluble in DMF. A mixture of the deuterized forms of these two solvents would 
have been an alternative to the water-acetone mixture, but due to difficult 
availability and an insufficiently promising outcome, we abandoned this 
approach. 
The characterization by NMR spectroscopy in a 1:1 mixture of D2O and acetone-
D6 suggested the coexistence of PDMS and a residue of the sugar. It could not 
be evaluated if the product still contained heparin, its decomposition product or 
other impurities. Nevertheless aggregation studies were performed by TEM 
imaging. 
TEM images were taken after producing a 1% solution through film rehydration 
method. Formation of spherical superstructures were observed, however, the 
nature of the superstructures could not be evaluated.  
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Figure 11: TEM images of heparin-PDMS aggregates 
 
TEM does not reveal if the superstructures are hollow (vesicles) or full spheres, 
therefore we measured the hydrodynamic radius (Rh) by DLS and the radius of 
gyration (Rg) with SLS.  
The DLS and SLS measurements were done on five solutions with a 
concentration gradient between 1 mg/mL and 0.1 mg/mL at angles between 30° 
and 150° (steps of 10°). For technical details and theory, see chapter 6.2.1.  
We measured and calculated a hydrodynamic radius (Rh) of 208 nm from DLS. 
SLS data were analyzed by Zimm plot, without (Figure 12a) and with (Figure 12b) 
considering a form factor. In the case where the form factor is not considered, the 
intensities, expressed by Kc/Rө are plotted against the angle, expressed by q2 
and extrapolated to 0°. The 0° intensities are then  plotted against the different 
concentrations and extrapolated to zero concentration. 
Figure 12a shows such a Zimm diagram. For clarity, only the values at zero 
scattering angles are plotted.  
Form the slope (s) and the intercept of the extrapolated graph, the mass 
averaged weight (Mw) and the radius of gyration (Rg) of the particles can be 
calculated: 
S = Rg2 / 3MW 
Thereby, we obtained a molar mass of approx 41’000 kDa. The radius of gyration 
was calculated to be 180 nm.  
 
In Figure 12b the extrapolations were done using the random coil form factor. 
The radius of gyration thereby was calculated to be 112 nm. 
 
 
CHAPTER 3  RESULTS
 
 
 26 
a)  
0
1
2
3
4
5
6
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
c [g/L]
(K
c 
(0°
)/R
) *
 
10
-
8
 
b)  
 normalized inverse scattering ratio, experimental
0.0E+00
5.0E-08
1.0E-07
1.5E-07
2.0E-07
2.5E-07
3.0E-07
0.0E+00 5.0E+14 1.0E+15 1.5E+15
q²+k ·C
K
C/
Rt
he
ta
 
 
(m
o
l/g
)
0.8
0.6
0.4
0.3
C=0
C=0
 
Figure 12: a) Static light scattering measurements of heparin-PDMS block-copolymer fitted 
without form factor. b) Fitted with random coil factor. The divergences of the fittings arise from 
high polydispersities, ranging from 0.15 to 0.25. 
 
The theoretical quotient of Rg/Rh is 1 in case of vesicles and 0.78 in case of full 
spheres.  
We obtained a quotient Rg/Rh of 0.87 without form factor and 0.54 with random 
coil form factor. Both results do not verify either – vesicle or full sphere – 
morphology. As we did not find any other than spherical shapes from this 
polymer by imaging techniques, we could not conclusively determine its 
aggregation behavior. 
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3.1.3 Heparin coupled to PDMS by DCC/DMAP method 
 
 
 
Figure 13: Synthesis pathway of PDMS grafted to heparin by DCC/DMAP method 
 
The attempts described so far - involving end-functionalization - resulted in rather 
low yields, were time consuming and difficult to reproduce. Therefore we decided 
to use dicyclohexyl carbodiimide (DCC) / 4-dimethylaminopyridine (DMAP) to 
couple the carboxylate functional groups of heparin to amino end-functionalized 
blocks via amide bonds70 (Figure 13). The DCC/DMAP coupling reaction is 
known from peptide synthesis. Being a one-pot reaction under mild conditions, it 
was a promising attempt to obtain higher yields and simpler purification, the 
drawback though being a more difficult quantification, considering that every 
second sugar unit is an iduronic acid possessing a carboxylate group, which is a 
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reacting group. The resulting amphiphile is best described as a graft block-
copolymer. 
The product was purified by UF and washed with hexane, resulting in poor water-
solubility, which indicated the formation of covalent bonds. NMR spectra were 
acquired to quantify the amount of coupled PDMS. A mixture of D2O and 
acetone-D6 was used as solvent, but the poor solubility of PDMS in acetone 
precluded a correct quantification. 
The formation of superstructures in water was observed by TEM imaging and 
measured by DLS, but the rather uncontrollable structures and sizes led to the 
idea to incorporate the polymers into the membrane of another polymer. 
 
Probing heparin functionalization of polymer vesicles by specific peptide binding 
 
Heparin-PDMS block copolymers are assumed to integrate into the membrane of 
vesicles formed by poly(ethylene glycol)-poly(propylene sulfide) (PEG-PPS) 
block copolymers, which were chosen because they are known to spontaneously 
form stable giant vesicles71. This polymer is an ideal candidate to be visualized 
by confocal microscopy. To verify the remaining bioactivity, we selected 
protamine because of its high affinity and specific binding to heparin leading to 
aggregation72. In medicine, it is used to inhibit the anticoagulant effect of 
heparin73. Protamines are small, highly positively charged peptides which bind to 
a variety of biological macromolecules, e.g. DNA. The used protamine, Salmine 
A1, consists of 32 amino acids, 21 of them are positively charged arginine 
residues which have a net charge of 21+ at physiological pH74. These residues 
form very strong ionic interactions with the sulfo- and carboxyl groups of the 
heparin75. To visualize the binding procedure, we labeled the membrane and 
protamine fluorescently with two dyes which emit at different wavelengths.  
To insert heparin-PDMS into a membrane made of PEG-PPS, three emulsions 
with different heparin-PDMS to PEG-PPS ratios were prepared. As a control 
experiment an emulsion with pure heparin and PEG-PPS was prepared. BODIPY 
was added to all solutions. Because of its high hydrophobicity, BODIPY 
incorporates into the polymer membrane labeling it (Figure 14).  
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Figure 14: The two fluorescent dyes OG 488 and BODIPY 630/650 enable to locate the PEG-
PPS membrane and the protamine. Heparin-PDMS diblock copolymers are integrated into the 
membrane 
 
Immobilized giant vesicles with diameters between 10-100 µm were formed on 
glass fibers. To verify the binding, protamine labeled with OG488 was added, as 
discussed below. 
 
Confocal Laser scanning microscopy - CLSM 
 
After incubating with labeled protamine, several images were taken at different 
time intervals. Because the image just shows the emission intensity of the dye, 
no quantitative conclusion about the binding could be drawn. On average, there 
were no observable differences between the samples with PEG-PPS to heparin-
PDMS ratios of 7, 30 and 76.  
The solution for the negative control was dissolved in chloroform. Then an 
emulsion with an aqueous solution of pure heparin was produced, before the 
glass fibers were dipped in it. The sample solution was done in a similiar way by 
mixing PEG-PPS in chloroform with an aqueous solution of heparin-PDMS.  
The fibers from both samples were dried in the drying oven over night and then 
immersed in 0.5 mL water76. Figure 15 a) and b) show the sample with heparin 
containing vesicles after 5 min and 20h. The negative control sample with pure 
PEG-PPS vesicles is shown in Figure 16 a) and b). The glass fibers which act as 
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a supporting medium for the polymer film are visible as green rods in the 
fluorescence images. The diagram next to the images shows the intensity 
development of both channels along the purple dart.  
 
a)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b)  
 
Figure 15: Heparin-PDMS and PEG-PPS, a) 5 minutes after incubation with protamine-OG488 
and b) 20 hours after incubation. The bright green areas are aggregated vesicles.  
The image dimensions are 230x230 µm. 
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a) 
 
b)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: PEG-PPS negative control, a) 5 minutes after incubation with protamine-OG488 and 
b) 20 hours after incubation. The green rods are the glass fibres. 
The image dimensions are 230x230 µm. 
 
The red curve displays the intensity of the membrane marking BODIPY dye and 
the green one the intensity of the protamine-bound OG488 dye. In the positive 
control it can be observed that the peaks of both channels are nearly congruent, 
whereas the peaks in the negative control show no correlation. Therefore, we 
concluded that most of the protamine was bound to the membrane of heparin 
containing vesicles while it was freely diffusing in the solution with plain PEG-
PPS vesicles. 
 
FCS/FCCS measurements 
 
Fluorescence correlation spectroscopy (FCS) and fluorescence cross correlation 
spectroscopy (FCCS) are powerful tools to determine the number, the diffusion 
properties and the molecular brightness of the species77-79 and were performed 
to measure the interactions between fluorescently labeled protamine and 
heparin-PDMS decorated PEG-PPS vesicles labelled with BODIPY 630. 
The samples were prepared by drying a solution of PEG-PPS in chloroform 
(control) or an emulsion of PEG-PPS in chloroform and heparin-PDMS in water 
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(samples) followed by rehydration. The solutions were extruded with a 0.2 µm 
Millipore filter. 
FCS data of protamine showed a diffusion time of 102 µs. Control vesicles had a 
diffusion time of around 3 ms whereas heparin-containing vesicles had a diffusion 
time of 7 ms, i.e. they seem to be larger. 
The binding was monitored by measuring FCCS of samples where the vesicles 
(both heparin- and control vesicles) were mixed with labeled protamine. The 
measurements suggested that there is some binding since the heparin-containing 
vesicles showed a high signal to noise ratio cross-correlation amplitude. The 
negative control vesicles did not, which indicates low binding. Also the diffusion 
times in the green channel were significantly higher in the positive control.  
The concentrations of vesicles, protamine and vesicles labeled with protamine 
were calculated from the measured number of molecules (Table 1). 
 
 Number molecules (N) Confocal volume (V) Concentration (c) 
Red channel NR = 0.52 VR = 3.1*10-19 m3 2.8 µM 
Green channel NG = 4.7 VG = 1.4*10-19 m3 55 µM 
Cross correlation NGR = 0.51 VGR = 2.1*10-19 m3 4 µM 
Table 1: Concentrations of fluorescently labeled materials and their cross correlation calculated 
from the number of molecules 
 
The concentration of vesicles bound to protamine calculated from the cross 
correlation is higher than the concentration of the pure vesicles (NR). This 
peculiar quantification result has to be handled precautiously, because the 
vesicles have a size that approaches the size of the light beam. When this 
happens, the characteristic diffusion time and the particle number in the light 
beam are larger than those expected from theory80. In other words, the measured 
concentration exceeds the real amount of vesicles that are bound to labeled 
protamine. Another factor that leads to an excessive detection of concentration is 
the cross-talk. This effect is caused, when the emission wavelength of one 
fluorophore (in this case OG488) overlaps with the excitation wavelength of the 
other fluorophore (BODIPY). 
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3.2 Heparin-PEE 
3.2.1 Heparin coupled to PEE by nitrous acid degradation followed by reductive 
amination 
 
As an alternative hydrophobic block to PDMS we used monofunctionalized 
poly(ethyl ethylene) (PEE). It was produced by hydrogenation of amino 
monofunctionalized poly(butadiene)81 on a palladium catalyst82. The coupling 
synthesis was carried out by degradation of heparin by nitrous acid, resulting in 
an aldehyde end-functionality of heparin, as described previously (chapter 3.1.1), 
and coupled to the amine end-functional PEE. 
The product was purified by preparative RP-HPLC and characterized by IR 
spectroscopy. The product was verified by IR (Figure 17), but the yield was 
extremely low. 
 
Figure 17:  IR spectra of heparin-aldehyde (black curve) and heparin-PEE (red curve): The band 
at 1738 cm-1 of the aldehyde functional group disappeared, the typical OH and NH bands at 
>3000 cm-1 from heparin as well as the CH bands of PEE are visible in the spectrum.  
 
Apart of its antifactor Xa activity (chapter 3.3.3), no further investigations were 
carried out with this copolymer. 
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3.3 Heparin-PEG 
3.3.1 Heparin coupled to PEG by triazine method 
 
The creation of a bis-hydrophilic compound, consisting of heparin as one and 
PEG as the other hydrophilic part, was supposed to be a model for the coupling 
of a hydrophobic block. The goal was to avoid handicaps caused by solubility 
differences between blocks, which lead to analysis problems. Furthermore, such 
bis-hydrophilic systems can also be considered amphiphilic due to their solubility 
differences in various solvents and may self-assemble in water, as for example 
the thermo-responsive micelles formed by poly(acrylic acid)-block-poly(N,N-
diethylacrylamide) block copolymers83. Self-assembly in dilute aqueous slolution 
into highly dynamic and rather well-defined spherical aggregates was also 
observed for poly(ethylene oxide)-block-poly(2-methyl-2-oxazoline) diblock 
copolymers. They can be viewed as swollen water micelles or as “nanogels”84. 
As reported earlier85, ionic self-assembly (ISA) bases on Coulombic interactions 
and heparin being a highly negatively charged polyelectrolyte is a promising 
candidate for the investigation of ISA.  
One possible method for coupling was using triazine as coupling reagent36 which 
was used by Bergman to control the amount of amino-functionalized polymers to 
hyaluronan. 2-Chloro-4,6-dimethoxy-1,3,5-triazine (CDMT), which is 
commercially available, can be used successfully for synthesizing esters, amides, 
and acid anhydrides from carboxylic acids86. 
The coupling of PEG was accomplished by the formation of amide-bonds 
between the carboxylic acid groups of heparin and the amine end-functionality of 
PEG 5000. One sample was synthesized with an equimolar amount of triazine to 
heparin. In the second sample, two equivalents of triazine were used. The 
amount of coupled PEG in the sample with excess triazine was supposed to be 
higher than in the sample with the equimolar amount of coupling agent. The NMR 
spectra of the products were evaluated by comparison of the anomeric protons of 
the idouronate and the glucosamine residues with the integral of the PEG peak. 
The sample with the excess triazine showed a ratio of average 1.7 PEG units per 
heparin, whereas the equimolar sample averages at 4.3 PEG units per heparin.  
The method did not result in the expected controllability. The amount of reacted 
PEG did not agree with the amount of applied CDMT.  
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The triazine method was supposed to be a good way to control the amount of 
PEG bound to heparin; however we did not really manage to achieve this 
controllability. 
 
3.3.2 Heparin coupled to PEG by nitrous acid degradation followed by reductive 
amination 
 
The unpredictable heparin to PEG ratio that resulted from the triazine-method, 
motivated another experiment based on nitrous acid degradation followed by 
reductive amination. The procedure is described in chapter 3.1.1. 
If heparin has one end-functionality, the aldehyde, to be coupled to a mono-
functionalized PEG block, we expected that the product would result in a 1:1 
heparin to PEG ratio (Figure 18). 
 
 
 
Figure 18: End-functionalized heparin coupled to monofunctional PEG 
 
The product was purified by UF, a method that resulted in an unsastisfactory 
removal of all unreacted blocks. HPLC purification was not accomplishable due 
to the insufficient separation of the products. 
The formation of a covalent bond between heparin and PEG was observed by IR. 
A peak at 1742 cm-1 appeared upon formation of heparin’s aldehyde end-
functionality and disappeared after the coupling step (Figure 19).  We performed 
NMR measurements, to compare the amount of bound and unbound PEG by 
end-group analysis. It showed that ca. 60% of the PEG molecules are coupled, 
the rest is present as free molecules. We assumed the same amount of heparin 
to be coupled and calculated the average length of the heparin molecules after 
the degradation reaction. We found a length of four remaining sugar residues. 
Considering, that a pentasaccharide is the bio-active fragment of heparin, we 
expect that the anticoagulant activity of the degraded heparin will drop to a 
minimum. This is confirmed by activity measurements in chapter 3.3.3. 
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Figure 19: IR spectra of heparin (red curve) with N-H and O-H bands at >3000 cm-1 heparin-
aldehyde (black curve), the aldehyde band appears at 1738 cm-1 and heparin-PEG (blue curve), 
the aldehyde band almost disappeared, the other typical bands are present 
 
As already mentioned, bis-hydrophilic copolymers are able to form 
superstructures in water. Heparin-PEG seemed to be an interesting candidate to 
investigate if the different polarities of the two blocks result in the formation of 
ordered structures. 
Heparin-PEG was dissolved in water and TEM-images were taken of highly 
concentrated solutions (30 mg/mL, Figure 20). The structures found indicated the 
formation of weakly bound superstructures, which coalesce upon drying.  
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Figure 20: TEM image of 30 mg/mL heparin-PEG. The formation of superstructures is 
presumably induced by drying effects 
 
DLS measurements - on the other hand - revealed that the superstructure 
formation was not detectable in solution. It can be speculated, that due to the 
hydrophilicity of both blocks the refractive index change and therefore the 
contrast for light scattering is too low to obtain a signal. The superstructures 
could also be too dynamic and thus the polymers can be considered dissolved in 
water, only interacting when the sample dries out. 
Formation of an ionic self-assembly was done by the addition of a multivalent 
metal-ion, which intereacts with the heparin parts, leaving the PEG-blocks to the 
interface. This way, a stabilized network was produced by mixing GdCl3 with 
heparin-PEG. The formation of such networks and also the salt’s aggregation 
behavior upon addition of phosphate was investigated by TEM and SEM/EDX. 
The purpose and applicability of such an aggregate will be discussed in 
paragraph 3.3.4. 
 
3.3.3 Antifactor Xa activity test 
 
As it has been stated above, a particular pentasaccharide sequence is necessary 
to maintain heparin’s anticoagulant activity. To see, what impact the performed 
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synthetic modifications as well as integration into a block-copolymer have, we 
compared blood coagulation activities for all heparin-hybrid materials.  
Heparin’s anticoagulant activity is mainly based on its ability to build a complex 
with antithrombin III (ATIII). The common point in both, the intrinsic and the 
extrinsic pathway of the blood coagulation cascade is the activation of factor X to 
factor Xa. Factor Xa gets inactivated by ATIII, when the coagulation process has 
ended and a clot forms. This inactivation gets potentiated 1000fold, when ATIII is 
bound to heparin. Therefore, a useful way of measuring heparin activity is to 
determine the amount of inactivated factor Xa in blood. Such a determination is a 
routine method in a haemostatic laboratory of a hospital. 
Blood is primarily mixed with a citrate-solution in order to complex calcium to 
prevent immediate coagulation. Then thrombocytes are removed by 
centrifugation, the leftover yellow solution is called citrate-plasma (Figure 21), 
naturally containing ATIII.  
 
Figure 21: Citrate plasma, obtained through centrifugation of my blood. 
 
A solution of heparin is prepared in the citrate plasma and a chromogenic 
substrate (S-2222) is added to the solutions. S-2222 is a tripeptide, bound to p-
nitroanilin, which can be degraded by factor Xa. P-nitroanilin gets detached from 
the tripeptide and, as free molecule, absorbs light at 405nm. 
Figure 22 illustrates the citrate plasma solution after the addition of the 
chromogenic substrate, heparin and factor Xa. According to heparin’s activity, a 
certain amount of ATIII gets complexed. When a well-known amount of factor Xa 
is added to the solution, one part gets deactivated by binding the heparin-ATIII 
complex and the rest detaches p-nitroanilin from the chromogenic substrate. 
Photometric determination of the free p-nitroanilin concentration leads to the 
amount of left-over anti-factor Xa and thus heparin-activity can be calculated. 
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Figure 22: Antifactor Xa activity test in citrate plasma. 
 
To prove the preserved biological activity of heparin and its derivatives, the 
following substances were subjected to antifactor Xa activity test: 
 
Substance     Abbreviation  Conc. stock solution 
LMWH (MW: 4000-6000 Da)  (LMWH)  1 mg/mL 
(PDMS-(C3H6-NH2)2) (MW: 5000 Da) (PDMS)  2 mg/mL 
Heparin-PDMS (by DCC/DMAP)  (H-PDMS)  1 mg/mL 
PEG-NH2 (MW: 5000 Da)   (PEG5000)  1 mg/mL 
Heparin-Aldehyde    (Hep-ALD)  1 mg/mL  
Heparin-PEG    (H-PEG5000) 3.5 mg/mL 
 
Table 2 shows the concentrations of active heparin in UI depending on the 
samples’ heparin concentrations. 
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LMWH H-PDMS Hep-ald H-PEG H-PEE PDMS 
c[mg/L] UI c[mg/L] UI c[mg/L] UI c[mg/L] UI c[mg/L] UI c[mg/L] UI 
15  >2 15 >2 500 0.48 300 1.26 15 0.00 15 0.00 
7.5 1.59 7.5 1.53 250 0.24 200 0.86 100 0.00   
5 1.38 5 1.12 100 0.07 100 0.42   PEG 
2.5 0.71 2.5 0.58 50 0.01 50 0.22   c[mg/L] UI 
1 0.28 1 0.2   15 0.05   15 0.00 
0.5 0.13 0.5 0.08         
Table 2: UI is the concentration of active heparin. It was measured at different sample 
concentrations. Pure LMWH was compared to varying heparin-hybrid molecules. 
 
LMWH was measured as bought and compared to heparin-PDMS (Figure 23). 
The activity of heparin-PDMS dropped by a factor of nearly two compared to pure 
heparin. This can be explained by the fact that half of the weighed material is 
inactive PDMS. 
As a control, we also measured pure amino-functionalized PDMS, which showed 
no activity, as expected. 
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Figure 23: Concentrations versus activity of pure heparin sample, heparin-PDMS (produced by 
DCC/DMAP method) and pure PDMS as control. To compare pure heparin with its aldehyde 
derivative, it is added in bright blue. 
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Heparin-aldehyde, on the other hand, shows a dramatic drop of anticoagulant 
activity. The reason is the segmentation of the polysaccharide where a major part 
of the bioactive pentasaccharide moiety is destroyed. In the case of heparin-PEG 
the activity was expected to drop to at least half of the original heparin-aldehyde 
activity, because of the PEG attached to the sugar. However, the drop was 
smaller than expected. The reason could be that the purification by UF was not 
sufficient and there are still unreacted heparin fragments present.  
As a control, we measured pure PEG-NH2, which showed no activity, as 
expected. 
We also compared the results to heparin-poly(butadiene), that was synthesized 
by nitrous acid degradation/reductive amination method as described above.  
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Figure 24: Concentration vs. activity of heparin-aldehyde (produced by nitrous acid 
degradation), heparin-PEG (PEG coupled to heparin-aldehyde by reductive amination) and as 
control: pure PEG. Note that the x-axis scale in Figure 23 differs from Figure 24. 
 
The aldehyde functionalized heparin that was used for coupling was from the 
same batch as used for the coupling to PEG, therefore we expected, that the 
anticoagulant activity would be the same. Yet the activity of PEE bound heparin 
was zero. It can be speculated, that the poor solubility of the block copolymer in 
the aqueous solution (blood plasma) could be one reason. Since the amphiphile 
was purified by HPLC and thus more thoroughly than the heparin-PEG, it has 
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also to be considered, that the heparin-PEG activity derives from unbound 
heparin, which was not removed by UF. 
 
3.3.4 Heparin-PEG for medical imaging 
 
Gadolinium is a well-known positive contrast agent (CA). It is highly 
paramagnetic due to its 7 unpaired electrons in the f-shell. As a CA it allows the 
surrounding protons (usually deriving from water) to relax faster, increasing the 
contrast and that way the quality of an MRI image. Gadolinium can not be applied 
in its pure ionic form because of toxic effects. It has to be protected by a stable, 
water-soluble and biocompatible shell. The commercially available positive CA’s 
are based on chelator-complexed ionic gadolinium. A new approach is to coat 
gadolinium by ionic interaction with a polyanion, such as heparin and form 
stabilized particles by adding phosphate, creating an insoluble gadolinium 
phosphate salt. 
The heparin-PEG polymer prepared by nitrous acid degradation followed by 
reductive amination was used as a matrix to trap positively charged metal ions.  
As an example of a biomedical application for glycopolymers, we studied a new 
type of MRI CA using stabilized GdPO4. In order to obtain a good CA it is 
necessary to decrease the mobility of the system87 and in this respect we used 
heparin-PEG block copolymers which trap the gadolinium nuclei inside their core. 
Figure 25 shows such a trapping system for stabilized GdPO4, however the 
dimensions and the exact shape are not assured. 
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Figure 25: GdPO4 stabilized by heparin-PEG diblock copolymer in water 
 
The general principle of magnetic resonance imaging (MRI) and CA’s was 
explained in the introduction. We will now introduce the heparin-PEG system with 
gadolinium ions and gadolinium phosphate as a potential new contrast agent. 
Before starting in vitro measurements with the copolymer/gadolinium system, we 
wanted to investigate how the polymer interacts with gadolinium ions and how 
gadolinium phosphate salt forms in the presence of the copolymer. Therefore we 
took TEM images of heparin-PEG with gadolinium (Figure 26) and gadolinium 
phosphate trapped in it (Figure 27).  
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Figure 26: TEM image of 30 mg/mL heparin-PEG and 0.5 mM GdCl3.  
 
 
Figure 27: TEM images of 30 mg/mL heparin-PEG and 2.5 mM GdPO4.  
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When the polymer was mixed with GdCl3 and applied to a TEM grid, the drying 
resulted in the precipitation of the salt inside the polymer structures. This 
indicates an interaction of gadolinium with the polymer in solution, but no 
superstructures form that were measurable by DLS. The addition of phosphate to 
the polymer-gadolinium solution results in the formation of an insoluble GdPO4 
salt, that is stabilized and kept in solution by the polymer. However, the polymer 
could not be seen anymore on the dried TEM grid. DLS measurements were not 
performed on this solution 
 
SEM/EDX studies 
 
Scanning electron microscopy is a technique where a high energy beam is 
focused onto the surface of a sample and signals from the interaction of the 
incident electrons with the sample’s surface are detected. The type of signals 
gathered in SEM can include secondary electrons, back scattered electrons and 
characteristic X-rays. 
The X-ray emission can also be used in energy dispersive X-ray microanalysis 
(EDX), which is an analytical technique for elemental analysis. The beam in the 
SEM excites an electron in an inner shell of an atom, promoting its ejection and 
resulting in an electron hole within the atom’s electronic structure. An electron 
from an outer shell drops into the hole and the energy difference is released as 
an X-ray beam with an energy that is characteristic for the two shells’ energy 
difference. Atoms with more than one shell can have several transitions and will 
result in several bands in the EDX spectra. The “Moseley plot of characteristic X-
rays” matches the detected X-ray radiation energies with the corresponding 
atoms (Figure 28). 
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Figure 28: a) Electron transitions to lower shells result in the release of X-ray radiation with a 
characteristic energy. b) Moseley plot of characteristic X-rays88. 
 
To gain information if heparin-PEG and gadolinium interact with each other, we 
acquired SEM images to see what shape the gadolinium phosphate 
superstructures have in the presence of the polymer. We also measured with 
EDX if the gadolinium phosphate aggregates are separated from the polymer or if 
they form a co-aggregate. The images were done on dry samples of heparin-
PEG mixed with GdCl3 and NaH2PO4 (Figure 29) and as a control, we aquired 
images and spectra of pure heparin-PEG (prepared by nitrous acid degradation 
followed by reductive amination, Figure 30), and pure GdPO4 (Figure 31).  
The original solutions contained 30 mg/mL heparin-PEG and 10 mM GdPO4 and 
were dialized against pure water to remove NaCl. 
Ca. 0.2 mL of the samples were dropped on the sample holder plate and dried 
over night. After silver-sputtering, SEM pictures and EDX measurements were 
performed. 
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Figure 29: SEM image and EDX spectrum of heparin-PEG (30 mg/mL) + GdPO4 (10mM).  
Scale bar (SEM): 500 nm 
 
 
 
 
 
 
Figure 30: SEM image and EDX spectra of Heparin-PEG (30 mg/mL)  
Scale bar (SEM): 500 nm 
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Figure 31: SEM image and EDX spectra of GdPO4 (10 mM) 
Scale bar (SEM): 300 nm 
 
It can be observed in the SEM images, that spherical aggregates are present in 
the mixed solution, whereas they are non-existent in the pure salt or the pure 
polymeric solution. The EDX measurement in Figure 29 indicates, that the 
polymer and the salt are not separated, because they were both detected at the 
same spot. In the control experiment with pure polymer, the SEM image shows a 
polymer layer that breaks upon electromagnetic radiation, the elements in the 
polymer were detected by EDX. The gadolinium phosphate control experiment 
reveals that the salt precipitates in a different, less defined shape than in the 
presence of the polymer. The EDX spectra shows, that no polymer is present, as 
no sulphur peak is visible. 
These results lead to further investigations of the interaction between gadolinium 
and heparin-PEG and the stabilization of gadolinium phosphate aggregates by 
the copolymer. Furthermore, we made a step towards understanding the 
applicability of stabilized Gd3+ and GdPO4 particles for medical imaging. To 
further investigate the stability and eligibility of such particles, EPR studies were 
performed. 
 
EPR studies 
 
EPR is a very powerful method for studying magnetic properties and crystal-field 
symmetry of species containing unpaired electrons, such as lanthanide(III) 
complexes89. For technical details and theory, see methods chapter 6. 
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In order to establish the complexation ability of the heparin-PEG copolymer to 
metals, we first used copper as a probe material, due to its capability to 
coordinate quickly to almost all kinds of organic ligands. It is an ideal metal to 
investigate interactions with various ligands, since it can adopt a large variety of 
geometries (e.g. square-planar, tetrahedral, pyramidal, trigonal bipyramidal etc.), 
to which its spin Hamiltonian is very sensitive. 
We mixed heparin-PEG with a solution of copper triflate (Cu(OTf)2) and 
immediately measured the spectrum at 125 K (Figure 32, line a). The simulation 
of this spectrum indicated an approximately axial symmetry of the first 
coordination sphere around the metal, with the gyromagnetic tensor g: 2.079; 
2.083; 2.395, and the hyperfine tensor A: 10; 10; 125 Gauss (G). The tensor of 
the linewidth, considered Gaussian, is Γ: 37; 38; 40 G. 
 
   
Figure 32: EPR spectrum of Cu(II) paramagnetic species formed between the copper ions and 
heparin-PEG block copolymer. a) experimental spectrum, b) simulated spectrum 
 
The values of the gyromagnetic tensor are specific for oxygen atoms in the first 
coordination sphere of copper. The axial symmetry of both gyromagnetic and 
hyperfine tensors is characteristic for a tetragonal geometry around the metal. 
As shown in Figure 32, the presence of the polymer leads to a paramagnetic 
copper(II), with >90% of Cu(II) being present in a tetragonal symmetry, with four 
oxygens in the first coordination sphere, which could derive from either PEG or 
heparin, since both blocks have such potential binding sites. 
Knowing that the polymer binds to copper, we measured spectra of GdCl3 
solutions and GdCl3 mixed with the copolymer to see how the overall shape of 
the spectra changes (Figure 33). 
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The EPR spectrum of GdCl3 has the characteristic quasi-isotropic lineshape, with 
a gyromagnetic effective factor of 1.982. This changes when the polymer is 
added to the GdCl3 solution, indicating, that Gd3+ is bound to the polymer. The 
pattern which appears at geff : 2.480 and 5.889, together with the normal signal at 
1.984 shows that the symmetry becomes lower when the metal is bound to the 
polymer. 
 
 
Figure 33: EPR spectra of a) GdCl3 and b) GdIII mixed with heparin-PEG 
 
To see if significant spin-spin interactions are present in GdIII, an EPR spectrum 
was measured as the function of temperature (Figure 34). The intensity of the 
high field signal decreases when the temparature increases from 110K to room 
temperature. This corresponds to a normal Curie behavior, specific to 
paramagnetic species. Thus, the spin-spin interactions can be considered small 
enough in the case of GdIII. 
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Figure 34: Intensity of EPR high field signal of heparin-PEG as the funcion of temperature. 
 
The transverse electronic relaxation rates, 1/T2e, were calculated from the 
dependence of the peak-to-peak EPR linewidths, ∆Hpp, as the function of 
temperature87 (Figure 35). 
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Figure 35: Temperature dependence of the transverse electronic relaxation rates of heparin-
PEG mixed with gadolinium 
 
Due to the fact that there is no reliable theory of electron spin relaxation in 
macromolecular GdIII systems, a detailed analysis of GdIII-GdIII distances is not 
possible, as is the case of low molecular weight GdIII complexes90. The 
experimental electron spin-spin relaxation rates measured here are higher than 
those for low molecular weight GdIII complexes. Therefore, besides the transient 
zero-field splitting mechanism91, the contribution from intramolecular Gd-Gd 
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interactions has to be taken into account. We suppose that the dipole-dipole 
contributions even if they are small, influence the electron spin relaxation rates 
and are modulated by the global rotational motion of the polymer system. 
EPR results prove that gadolinium interacts with oxygen atoms, but as both 
blocks of the polymer contain oxygen atoms, it is impossible to show where 
exactly the binding takes place. However, due to the opposing charges, we 
assume that the interaction is more likely to happen between the Gd and heparin. 
Further indications that gadolinium is bound to the heparin block of the copolymer 
are presented in the MRI section below. 
 
MRI studies 
 
We used the bis-hydrophilic heparin-PEG copolymer as a matrix for gadolinium 
ions and gadolinium phosphate particles. The hydrophilic character of the block-
copolymers ensures retention of water molecules in proximity of the 
paramagnetic core giving high relaxivity. When Gd3+ is present freely in the body, 
it interacts with phosphate and is cytotoxic. It also accumulates in the bone 
tissue. Phosphate addition results in formation of small gadolinium-phosphate 
particles with a solubility constant of 10-25 mol2/L2, meaning, that they are virtually 
insoluble92 in aqueous solution. This reduces the toxicity. 
These GdPO4 bearing copolymers can be produced by mixing GdCl3 with a 
solution of or the block copolymers, followed by an addition of PO43-. 
We assume that when Gd3+ ions are mixed with an anionic block-copolymer, they 
form a network through electrostatic interactions, which is maintained in solution 
and shielded by the uncharged block at the water-polymer interface. When 
phosphate is added to this solution, gadolinium phosphate particles grow until 
they reach the dimension of the core of the polymer-shielded aggregate, around 
a few nm.  
To further explore the possibilities to form such coated gadolinium phosphate 
particles, we also used a polycation, polylysine, bound to PEG and mixed it first 
with PO43- before addition of GdCl3.  
When PO43- ions are mixed with a cationic block-copolymer, they form a similar 
network, with the uncharged blocks at the interface. Addition of Gd3+ to 
polylysine-PEG results in the fomation of assumedly crystalline particles, that are 
arranged in a star shape (Figure 36). The organization is probably deriving from 
the interaction with the polymer. We wanted to see if the gadolinium phosphate 
particles remain stable also when they are produced in a different way.  
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Figure 36: TEM image of gadolinium phosphate particles stabilized by polylysine-PEG 
 
Those aggregates, produced by either method, remain in solution due to the 
hydrophilic uncharged block. Depending on the concentration, the solutions 
remain stable in aqueous solution for at least 2 weeks without phase separation. 
We will not discuss the polylysine-PEG block copolymer in detail, because it 
seems to be less promising for medical use, due to polylysine’s cytotoxicity. We 
will discuss the results obtained by MRI measurements to demonstrate the 
feasibility of gadolinium phosphate aggregates with a polycation-PEG copolymer. 
 
We prepared different concentrations (0.1 mM to 1 mM) and concentration ratios 
(1:1, 1:2 and 1:5) of GdCl3/GdPO4 and heparin-PEG (and PEG-polylysine, 
respectively) and measured as a control solutions of GdCl3 without the polymer, 
the pure polymer and also pure water. As expected, the polymer and the pure 
water showed no enhancement of the relaxivity and therefore those samples will 
not be further mentioned anymore. 
As further control experiments, we did the same measurements with simply PEG 
and heparin. For clarity, the different measurements are schematically 
represented in Figure 37. All measured samples are listed in Table 3. 
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Figure 37: Schematic representation of the sample preparations for MRI measurements. The 
solutions were mixed with GdCl3, the relaxivity was measured, then Na2HPO4 was added and the 
relaxivity was measured again. a) heparin-PEG solution, the added salts are stabilized by the 
copolymer. b) heparin forms a network with Gd3+, which is destroyed upon addition of phosphate. 
The salt precipitates. c) PEG does not interact with Gd3+, addition of phosphate results in 
immediate precipitiation of the salt. d) PEG-polylysin stabilizes phosphate, addition of gadolinium 
leads to stabilized salt particles. 
 
Eppendorf test tubes filled with aqueous solutions (concentrations of 0.01, 0.1, 
0.2, 0.3, 0.4, 0.5, 1 mM) of heparin-PEG complexed with GdCl3 and GdPO4 with 
multiple concentration ratios between polymer and Gd3+ and GdPO4 salt (5:1, 2:1, 
1:1) were scanned on a 1.5T imaging scanner, in order to evaluate the R1 and R2 
relaxation rates.  
By measuring the relaxivities at different concentrations (Figure 38 shows the 
relaxivities R1 of mixtures of heparin-PEG/Gd3+ and heparin-PEG/GdPO4) and 
plotting them against the concentration, we can calculate R1,0 and R2,0 from the 
intercept of the linear regression and the concentration independent relaxivities r1 
and r2 from the slope. 
 
01,2 1,2 1,2
R R r C= +
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Figure 38: The relaxivities of heparin-PEG/Gd3+ and heparin-PEG/GdPO4 mixtures at different 
concentrations are in a linear relation to each other. 
 
These concentration-independent relaxivities can be used to compare different 
systems. As a control, we also measured pure Gd3+ (relatively low contrast) and 
GdPO4 (immediate precipitation and loss of contrast). This control experiment 
emphasizes the need for stabilizing agents for gadolinium species, such as our 
copolymer.  
In Figure 39, we compared our systems to other CA’s, Magnevist®, Gadovist® 
and MultiHance® being commercially available CA’s93 and new CA’s, investigated 
by other research groups51. 
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Figure 39: Relaxivities r1 and r2 of heparin-PEG and Gd3+/GdPO4 at different ratios compared to 
other CA’s. [*:ref 93; **: ref 51] 
 
The relaxivities seem to depend on the ratio between the polymer and the metal. 
This can be explained by the fact, that if the amount of polymer is not sufficient to 
bind all metal ions, the unbound ions will only contribute slightly to the relaxivity, 
as they are small and their rotation freedom is not limited. It is also noticeable 
that the relaxivities drop upon addition of phosphate. One reason is that the 
unbound ions will precipitate and not contribute at all anymore. The other reason 
could be that aggregates form and the gadolinium atoms inside of the particles 
are not anymore accessible for the exchange with water molecules. Thus, the 
gadolinium concentration theoretically drops. 
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Figure 40: Relaxivities r1 and r2 of heparin-PEG and Gd3+/GdPO4 compared to PEG and 
Gd3+/GdPO4.  
 
The measurements were also compared to mixtures of gadolinium and its 
phosphate salt with pure PEG (MW: 5000 Da) (Figure 40). The results show that 
mixing PEG with Gd3+ leads to only minor relaxivity change compared to free 
Gd3+. The 5:1 mixture of PEG with GdCl3 results in almost complete loss of the 
relaxivity and seems to be an outlier, because no precipitation was observed. 
The results after the addition of phosphate are not reproducible due to the fact 
that GdPO4 salt was precipitating and the relaxivities were not in a linear relation 
(Figure 41).  
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Figure 41: The relaxivities of PEG/Gd3+ differ only insignificantly from free Gd3+. PEG/GdPO4 
mixtures are not in a linear relation to each other due to precipitation. 
When PEG is mixed with a metal ion, there are no negative charges to interact 
electrostatically, therefore no macromolecular aggregates form with the ion and 
the mobility is not restricted. This leads to no increase in relaxivity compared to 
free gadolinium ions.  
 
The change of relaxivity was also measured with mixtures of heparin and 
Gd/GdPO4 and compared to the results with the heparin-PEG copolymer (Figure 
42). The r2 were extremely high for mixtures of heparin and gadolinium ions, up 
to 140/mM*s (for clarity, the scale is only shown up to 100/mM*s). The negative 
charges on heparin lead probably to the formation of a loose network, limiting the 
mobility of gadolinium ions to a very high extent (cf. Figure 37 b). That is the 
reason why the relaxivity increased so much when the gadolinium ion is mixed 
with heparin. But since the network is not stabilized by surrounding PEG blocks, 
the addition of phosphate leads to the formation of big gadolinium phosphate 
aggregates. Their growth is not limited by the formation of polymer-gadolinium 
compartments, therefore the salt precipitates. The relaxivity drops dramatically. 
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Figure 42: Relaxivities r1 and r2 of heparin-PEG and Gd3+/GdPO4 at different ratios compared to 
heparin.  
 
These results showed that we produced a system with an excellent relaxivity 
compared to commercially available CA’s. This enhances the signal-to-noise 
ratio, allowing enhancement of the spatial resolution and gives the opportunity to 
decrease the concentration of gadolinium and thus make the system less harmful 
for human use. The toxicity can be further lowered by the addition of phosphate, 
because it forms an insoluble salt with gadolinium.  
The control measurements with heparin and PEG supported the assumption that 
a copolymer with one negatively charged block and a neutral block are necessary 
to form a stabilizing aggregate and keep the salt in solution. We also confirmed 
by the measurements with pure heparin that the interaction of gadolinium and 
oxygen takes place with the negatively charged oxygen atoms on heparin and 
PEG does not or negligibly interact with the metal ions. 
 
Gadolinium phosphate nanoparticles were also prepared by formation of 
phosphate-polymer superstructures and then mixing with gadolinium. Obviously, 
we needed a polycation to interact with the negatively charged phosphate. We 
chose poly-L-lysine (MW: 20’000-30’000 Da) grafted with PEG (MW: 5000 Da) 
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blocks. Ca. 60% of the amino groups of poly-L-lysine are occupied by PEG 
(Figure 43). 
 
 
Figure 43: GdPO4 aggregates stabilized by poly-L-lysine compared to GdPO4 in heparin-PEG. 
The relaxivities remain stable for 2 weeks. 
 
Stable particles did form, although the relaxivities are lower than with the heparin-
PEG copolymer. 
Those polymer-GdPO4 aggregates, produced by either method, remain stable in 
solution for up to 2 weeks without phase separation. 
Thorough stability studies were performed with different concentrations / ratios of 
polymer-gadolinium. Each sample was measured immediately after preparation, 
then again after 1.5h and again after 2 weeks. Some of the samples showed an 
immediate phase separation, visible by eye; some of them only after some time. 
In Table 3, we compared the stabilities of all samples and concentrations 
depending on how much time passed between preparation and measurement.  
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  1 mM 0.5 mM 0.4 mM 0.3 mM 0.2 mM 0.1 mM 0.01 mM 
Gd3+               
GdPO4               
Hep-PEG+Gd3+ 5:1                
Hep-PEG+Gd3+ 2:1                
Hep-PEG+Gd3+ 1:1                
Hep-PEG+GdPO4 5:1                
Hep-PEG+GdPO4 2:1                
Hep-PEG+GdPO4 1:1                
PEG+Gd3+ 5:1                
PEG+Gd3+ 2:1                
PEG+Gd3+ 1:1                
PEG+GdPO4 5:1                
PEG+GdPO4 2:1                
PEG+GdPO4 1:1                
Heparin+Gd3+ 5:1                
Heparin+Gd3+ 2:1                
Heparin+Gd3+ 1:1                
Heparin+GdPO4 5:1                
Heparin+GdPO4 2:1                
Heparin+GdPO4 1:1                
PLys-PEG+Gd3+ 1:1                
PLys-PEG+GdPO4 1:1                
        
    no precipitation    
        
    precipitates immediately   
    precipitates after 1.5h   
    precipitates after 2 weeks   
        
    not measured    
Table 3: Stability studies on all measured polymers with gadolinium ions and gadolinium 
phosphate. All samples were measured three times: freshly prepared, after 1.5 h and after 2 
weeks. 
The samples with copolymer – heparin-PEG and PEGpoly(lysine) – remained in 
solution (green) even after addition of phosphate, however, the stability is not 
given at higher concentrations. Furthermore the ratio between copolymer and salt 
seems to play a role for solubility. 
Pure PEG and pure heparin are not able to keep the salt in solution. All samples 
precipitated immediately after preparation.  
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3.4 Glycopeptide 
 
Another class investigated in this thesis was a combination of a short helical 
peptide with a sugar moiety. The initial idea was to combine heparin with a 
truncated derivative of gramicidin A, the peptide W-(DL-W)3 (TRUNK). The β-
sheet like folding motif combined with the presence of a D-amino acid (D-leucin) 
results in the channel structure as illustrated in Figure 44.  
 
Figure 44: TRUNK, view along the helical axis of the peptide. The channel has an inner 
diameter of ca. 6.6 Å.55 
 
At the same time we wanted to find simple and reproducible reaction conditions 
to couple a sugar to a peptide.  
As heparin turned out to be difficult to handle and would have been too long a 
hydrophilic block for the peptide, we decided to take the two main building blocks 
of GAGs, the monosaccharides D-glucuronic acid and D-glucosamine (Figure 45) 
as carbohydrate coupling models. 
 
a) 
O
O
OH
OH
OH
OH
HO
 
b) 
 
 
Figure 45: a) D-glucuronic acid and b) D-glucosamine 
 
The peptide was chosen because of its known self-assembling properties as 
shown by Dittrich et al.59 with oligo-lysine as a hydrophilic block. We were 
interested, how the self-assembly changes if the hydrophilic block is an 
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uncharged saccharide and wanted to find new ways to couple sugars to a 
peptide. 
 
3.4.1 Coupling D-glucuronic acid (GluAc) to the TRUNK 
 
TRUNK-GluAc was synthesized by Fmoc SPPS on Rink Amide AM resin in DMF 
using HCTU as a coupling agent and DIPEA as a base (Figure 46). GluAc was 
dissolved in formamide and coupled the same way. Cleavage from the resin and 
removal of the protecting groups was carried out with 95% TFA, Triethylsilane 
(TES) as scavenger and H2O. The residual crude product was dried over night in 
a desiccator. 
. 
O
O
OH
OH
OH
OH
HO
NH
O
TRUNK-NH2
Rink amide AM
1. HCTU/DIPEA
    DMF
+
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H
N
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H2N
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Figure 46: Scheme of the SPPS coupling reaction of the sugar to W-(DL-W)3 (TRUNK) 
 
The glycopeptide was purified and analyzed by HPLC on reverse phase columns 
(Figure 47), collected and then identified by MALDI-TOF (Figure 48).  
 
 
Figure 47: Analytic HPLC run with the 96% pure product peak  
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Figure 48: MALDI-TOF diagram of TRUNK-GluAc after purification. 1300 Da correspond to the 
sodium salt of the molecule ion 
 
The analytical HPLC diagram shows, that we obtained the product in a purity of 
95%. The correct product mass was detected by MALDI-TOF. The TRUNK has a 
molar mass of 1079.26 g/mol and the d-glucuronic acid 194.14 g/mol. With 
sodium as counter ion the molar mass corresponds to 1296.26 g/mol. 
Protonation of the tryptophane amino acids adds up to 1300.26 g/mol, which is 
what we measured by MALDI-TOF. 
 
Membrane self-assembly 
 
Glucuronic acid was chosen as the hydrophilic part because of the possibility to 
couple the acid functional group to the peptide by the same synthetic pathway as 
the peptide itself on solid phase. This simple and effective synthesis strategy 
leads to high yields. Moreover, the uncharged head group avoids unfavourable 
electrostatic repulsion when superstructures form. 
However, dialysis of an ethanolic solution of the glycopeptide against pure water 
led to formation of particles, which aggregate and finally precipitate. DLS 
measurements still revealed a hydrodynamic radius around 250 nm and 
polydispersities around 1, but lacking a concentration specification, the fits could 
not be reliably accomplished.  
LSM images were taken by excitation of the tryptophane at λ = 280 nm. The 
uniformly round particles could be very clearly seen by eye, but due to Brownian 
motion, no sharp picture could be taken (Figure 49). 
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Figure 49: LSM image of a glycopeptide solution prepared by dialysis against pure water 
 
In order to avoid the precipitation of the particles we used 10% EtOH in water as 
the solvent. Nevertheless, after a few days we observed a slight sedimentation. 
From DLS measurements, a hydrodynamic radius of 176 nm was calculated.  
The particles were observed by LSM, their size corresponded to the size 
measured by DLS, but similar to the samples in water, no sharp images could be 
acquired (Figure 50).  
 
 
Figure 50: LSM image of a glycopeptide solution in 10% EtOH 
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To further investigate a suitable solvent for the particles, where sedimentation 
doesn’t take place, we dialyzed against 20% EtOH. The solution remained 
opalescent with no sedimentation even after one week. The particles have a 
radius of 137 nm according to DLS. LSM imaging (Figure 51) supports those 
results, although the concentration of the particles seemed to be lower than with 
pure water or 10% EtOH as solvent. This could be explained by the fact, that 
more molecules stay in solution as the ethanol concentration is increased. 
 
 
Figure 51: LSM image of a glycopeptide solution in 20% EtOH 
 
Since the LSM images in all solutions remained diffuse and the resolution was 
not high enough to see details, we did TEM imaging. 
The solutions in pure water (Figure 52) revealed aggregates in the size range 
that was measured by DLS. It was surprising that in the edges of the particles 
were not smooth. A reason could be that in pure water crystallization is initiated 
that influences the shape. Contrariwise, this could also be a drying effect.  
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Figure 52: TEM images of a glycopeptide solution prepared by dialysis against pure water 
 
In a solution of 10% EtOH (Figure 53), the particles are spherical and after some 
time they aggregate. In the TEM image, they seem to aggregate and form a 
network. A polymer film that contracts upon drying could explain this 
phenomenon. The size of the particles corresponds to the size that was 
measured by DLS. 
 
  
Figure 53: TEM images of a glycopeptide solution in 10% EtOH 
 
In the TEM pictures from a solution of 20% ethanol, the shapes become blurry 
and aggregate (Figure 54). It can be speculated, that the high amount of ethanol 
leads to the formation of loose particles that aggregate in an undefined shape 
upon drying. 
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Figure 54: TEM images of a glycopeptide solution in 20% EtOH 
 
We also attempted atomic force microscopy (AFM, Figure 55) and cryo-TEM 
(Figure 56) with the solution in 10% EtOH to get further insights into the nature of 
the superstructures.  
 
 
 
Figure 55: AFM images of a glycopeptide solution prepared in 10% EtOH 
 
We found small spheres on a graphite surface by AFM, which did not correspond 
to the size of the aggregates we measured before by DLS and TEM. They were 
considerably smaller. We conjectured that a mono- or multilayer of glycopeptide 
formed on the surface by hydrophobic interaction of the peptide with the graphite 
surface. The particles are then assumed to be packed in the layer.  
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The particle radius could be calculated with the height and the diameter of the 
segment of those spheres. The radius (r) of a sphere can be calculated from the 
segment’s height (h) and its diameter (a):  
 
 
 
r = (a2 + 4h2) / 8h 
 
 
 
 
 
 
The diameters (a) of the segments range between 50 nm and 60 nm, their 
heights between 1.8 and 2.5 nm. Taking two mean values: 55 nm for the 
diameter and 2.2 nm for the height, we obtain a particle radius of 173 nm, which 
corresponds well with the data measured by DLS (Rh = 176 nm).Cryo-TEM 
images showed structures which could be interpreted as the particles (Figure 56). 
The network that we saw in the TEM images was also observed in the cryo-TEM 
images; however the sizes are slightly smaller. Furthermore, the differentiation 
from water-crystals is not ensured, therefore the interpretations have to be 
handled with care. The large feature in the background is the supporting carbon 
film. 
 
 
Figure 56: Cryo-TEM image of a glycopeptide solution prepared by dialysis against 10% EtOH. 
r
h
a
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In summary, we developed a simple and effective glycopeptide synthesis method 
by coupling D-glucuronic acid to the N-terminus of the TRUNK on solid phase. 
The glycopeptide self-assembles when dialyzed against pure water and solutions 
of 10% EtOH and 20% EtOH. In pure water, the particles form, but most of them 
immediately aggregate and precipitate. By increasing the amount of EtOH in the 
solvent, the aggregation can be prevented. However, since the glycopeptide is 
soluble in EtOH, there is a limitation of the ethanol ratio. The nature of the 
superstructures could not be definitely determined, but there are indications that 
we did not obtain vesicular structures. The particles could be of compound 
micellar structure or particles formed by glycopeptide multilayers. 
 
3.4.2 Coupling D-glucosamine to the TRUNK (W-(DL-W)3) via carboxylate 
 
The first attempt to couple the monosaccharide D-glucosamine to the TRUNK 
was done in solution by synthesizing the peptide by Fmoc solid-phase synthesis 
(SPPS) on 2-chloro trityl chloride, which results in a carboxylate functionality at 
the C-terminus upon cleavage. The SPPS was carried out in DMF, with HCTU 
and coupling agent and DIPEA as base.  
After cleavage from the resin with 0.5%TFA in DCM and evaporation of the 
solvent, the peptide was dissolved in DMF and D-glucosamine in formamide was 
added. Addition of HCTU and DIPEA was supposed to result in the formation of 
an amide bond between the amino functionality of the sugar and the carboxylate 
of the peptide. The product was characterized by MALDI-TOF (Figure 57) and 
analytical HPLC. 
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Figure 57: The product with a molar mass of 1495 Da could be identified by MALDI-TOF-MS. 
 
The product with a molar mass of 1495 could be detected by MALDI-TOF-MS, 
but the amount was too low to be detected in HPLC. Therefore we tried another 
synthesis strategy to couple D-glucosamine. 
 
3.4.3 Coupling D-glucosamine to the TRUNK via reductive amination 
 
 
Figure 58: Formation of an aldehyde end-function on D-glucosamine with nitrous acid. 
 
As a first step, D-glucosamine was supposed to be functionalized to result in an 
aldehyde, which then could be coupled to carboxylate via reductive amination 
(Figure 58).  
The reaction of D-glucosamine with nitrous acid seemed to work, because we 
could observe the formation of nitrogen bubbles. But after drying the product, we 
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found a brown-black residue, which according to IR did not contain aldehyde 
functions. 
We assumed that the low pH, which dropped further by evaporation of the water 
could result in a side reaction, hence we raised the pH back to 7 before removal 
of the water. The yellow residue turned out not to be an aldehyde again. 
An explanation for the failure of this approach is probably that the aldehyde 
attacks the amine group of unreacted D-glucosamine nucleophylically. In this 
process a Schiff’s base forms, resulting in a “disaccharide”. 
To avoid this reaction, we used an acetylated D-glucosamine to protect the 
amino groups.  
In heparin, most of the glucosamine moieties are also acetylated; therefore we 
assumed that the aldehyde formation should still be possible. The reaction with 
N-acetly-D-glucosamine () was carried out in the same way as the one with D-
glucosamine, but no bubbles formed. IR spectroscopy revealed that no reaction 
took place.  
 
 
Since we did not manage to produce a stable aldehyde-functionalized D-
glucosamine, we tried the reductive amination with pure D-glucosamine. As 
sugars in solution are in equilibrium of the α- and β- anomeric forms and the 
transition is an open conformation with an aldehyde functionality, we hoped, that 
this would be enough to react with the N-terminus of the TRUNK.  
The TRUNK was synthesized by Fmoc SPPS on Rink Amide AM resin. 
After the last coupling step, the N-terminal tryptophane was deprotected and a 
solution of D-glucosamine in water was added with a small amount of sodium 
cyanoborohydride. After cleavage from the resin and purification, the residue was 
analyzed by MALDI-TOF-MS and analytical HPLC. No product could be 
detected. 
 
 
 
Figure 59: N-acetyl-D-glucosamine did not react to the aldehyde. 
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4 CONCLUSIONS 
 
Heparin was coupled to hydrophobic and hydrophilic blocks by different synthesis 
approaches. Because of the strongly polar character of heparin, it is only soluble 
in very polar solvents such as water and formamide. This restricts the choice of 
hydrophobic blocks and the analysis methods. 
Coupling of heparin to PDMS could be achieved, but the purification and 
quantification still remain improvable. DCC/DMAP coupling turned out to be a 
simple one-pot-reaction with retention of heparin’s anticoagulant activity, as was 
proven by antifactor Xa activity test in citrate plasma. Binding to ATIII was 
observed and stoichiometry suggests a heparin/PDMS ratio close to 1:1. 
The insertion of this glycopolymer into the membrane of polymeric vesicles 
formed by PEG-PPS was successfully achieved. Fluorescently labelled 
protamine salmine A1, a small, positively charged peptide with a high binding 
affinity to heparin was used to visualize the interaction with heparin-coated 
vesicles by confocal microscopy. FCS/FCCS measurements confirmed the 
interactions of heparin within the superstructures. 
 
Coupling of heparin to the hydrophilic PEG block was achieved by nitrous acid 
degradation, where a major part of the bioactive pentasaccharide moiety gets 
segmented and heparin looses most of its anticoagulant activity. The activity loss 
could be measured by antifactor Xa activity test. 
Nevertheless, the bis-hydrophilic compound was investigated in terms of its self-
assembly behavior and interaction of the negatively charged heparin functional 
groups with the positively charged Gd3+ ion. TEM images showed that the 
copolymer forms highly dynamic superstructures, which after interaction with 
gadolinium ions, seem to become more organized. The copolymer influences the 
shape of GdPO4 particles, resulting in spherical aggregates, as could be 
observed by SEM imaging.  
EPR measurements showed that gadolinium was stably bound to oxygen atoms 
of the polymer, suggesting that aggregates with heparin and gadolinium in the 
core and PEG exposed to the surface had been formed.  
We made a new type of MRI contrast agent based on block-copolymer stabilized 
Gd3+ or GdPO4 particles. In vitro MRI measurements showed that the polymer-
gadolinium aggregates enhance the proton relaxivity to a very high extent. The 
relaxivities are much higher than for commercially available CA’s, therefore the 
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amount of gadolinium can be decreased, making the system less harmful for 
human use. Heparin’s activity loss upon degradation further enhances the 
potential of those aggregates as CA because blood coagulation activity would be 
an undesirable side effect for the use as a CA. 
Addition of phosphate leads to small salt aggregates which remain dispersed due 
to the stabilization by the heparin-PEG polymer and further lower the toxicity of 
gadolinium ions. Control experiments with heparin and PEG support the 
assumption that the copolymer with one charged block and a neutral block are 
necessary to stabilize the salt particles in solution. 
 
Saccharides were also studied as building blocks for glycopeptides. 
Two new methods were investigated to couple D-glucosamine to the TRUNK (W-
(DL-W)3). The first one involved coupling in solution by obtaining a carboxylic 
acid function on the TRUNK after cleavage from chlortrityl chloride. Then, D-
glucosamine was coupled with HCTU. The resulting product was detectable but 
not sufficient to be purified.  
As a second trial we attempted to functionalize the sugar to obtain an aldehyde 
end-functionality and then couple it via reductive amination to the N-terminus of 
the TRUNK, but the aldehyde functionalized sugar reacted with the educt to form 
a Schiff’s base resulting in a disaccharide. We tried to avoid this side-reaction 
with an acetylate-protected D-glucosamine. This attempt resulted in no product. 
Therefore we did the reaction with non-functionalized D-glucosamine, but no 
coupling took place.  
 
As the second monosaccharide, we chose glucuronic acid (GluAc), to be coupled 
to the TRUNK. The amphiphilic glycopeptide (W-DL)3-W-GluAc was synthesized 
and purified. The coupling was accomplished by the formation of an amide bond 
between the carboxylic acid group of D-glucuronic acid and the N-terminus of the 
peptide on solid phase with HCTU as coupling agent and DIPEA as the base. 
The glycopeptide was investigated in terms of its self-assembly behavior and was 
found to form spherical structures after dialysis from EtOH. The superstructures 
aggregated and precipitated in pure water. Ethanol-in-water solutions of 10% and 
20% as solvents prevented precipitation. TEM, cryo-TEM and LSM images 
supported the formation of spherical aggregates; their sizes were confirmed by 
DLS. 
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In summary, we combined saccharides with synthetic and peptidic blocks to 
produce new materials. We explored new synthesis and characterization routes, 
studied the self-assembly and investigated potential applications of those 
substances. 
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5 OUTLOOK 
 
Even though the synthesis of heparin-based block copolymers was successfully 
achieved, the characterization and especially the purification turned out to be 
difficult and can be further improved. The variation of the hydrophobic block in 
the case of the amphiphiles can simplify those factors. For example, if a 
hydrophobic block is chosen, which is soluble in a co-solvent (mixture) with the 
hydrophilic block, a wider range of applicable purification and characterization 
methods would be accessible.  
Instead of heparin, a wide range of other polysaccharides can be introduced as 
hydrophilic blocks and investigated in terms of their properties, especially in 
terms of bioactivity.  
 
For the MRI measurements, different polyelectrolytes coupled to PEG can be 
investigated to stabilize gadolinium. It will also be investigated if the gadolinium 
phosphate aggregates are crystalline or amorphous to understand what the 
nature of the aggregates is. In the perspective of applicability for medical 
imaging, in vitro and in vivo toxicity experiments, adsorption and elimination 
studies followed by clinical research assays are essential.  
 
After prosperous development of a new glycopeptide synthesis and its 
characterization, further elucidation of their aggregation behavior is key 
information in terms of their applicability as e.g. vaccine. The folding motif and di- 
or multimerization in water of glycopeptides and peptides based on gramicidin 
and its derivatives is the topic of ongoing investigations. This information would 
deliver conclusions about the still inexplicit superstructure formation behavior. 
Further on, a variation of the coupled sugar and its length would lead to new 
materials with interesting self-assembly properties. 
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6. METHODS 
 
6.1 Syntheses  
 
6.1.1 Heparin coupled to PDMS by degradation and reductive amination 
 
200 mg Heparin (MW: 5000Da, 40 µmol) was dissolved in 60 mL H2O in a 100 
mL round flask at RT, followed by addition of 2 mg NaNO3. The pH was adjusted 
to 2.7 using 1M HCl and the solution was stirred for 24h at RT. 
Then NaOH was added until pH 7 was reached. 
Upon ultrafiltration (cut-off 1000 Da), followed by lyophilization on a Heto Maxi 
Dry Lyo, heparin-aldehyde was obtained.  
40 mg (8 µmol) heparin-aldehyde was dissolved in 25 ml 0.15M NaCl solution. 
20 mg (4 µmol) PDMS-(C3H6-NH2)2 (MW=5000Da) was dissolved in 25 mL 
EtOH. After mixing the two solutions, pH was adjusted to 3.5  
20 mg (0.32 µmol) of cyanoborohydride was added and the solution was stirred 
at 50°C. After 24h, the solution was ultrafiltrated  (cut-off 10’000 Da). 
Lyophilization led to 37 mg heparin-PDMS (2.5 µmol). 
 
6.1.2 Heparin coupled to PDMS by iodine method 
 
200 mg heparin (40 µmol) was dissolved in 1mL H2O and passed through a 
Dowex 50X8 (H+) column. After lyophilization, 200 mg I2, dissolved in 100 mL 
20% MeOH was added. 
The reaction mixture was stirred over night at room temperature. 
The solution was filtered through a paper filter to get rid of undissolved iodine and 
lyophilized for 5h to reduce the volume.  
Then the solution was poured into 200 mL 20% EtOH containing 8g (4% (w/v)) 
KOH and the solution was subjected to ultrafiltration (cut-off 3000 Da). Upon 
freeze-drying of the ultrafiltered solution, oxidized heparin was obtained. The 
product was dissolved in 2 mL water and passed through a Dowex 50X8 (H+) 
column. Upon freeze-drying the eluate, lactone-heparin was obtained. 
100 mg lactone-heparin was dissolved in 5 mL DMF. 
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50 mg NH2-PDMS-NH2 was dissolved in CHCl3 and added to the lactone-heparin 
solution. 0.1 mL tri-n-butyl amine was added to the reaction mixture and stirred 
for 8h at 80°C.  
The reaction mixture was dried and washed with hexane. The residue thus 
obtained was dissolved in water and passed through a Dowex 50X8 (H+) column. 
The eluate upon ultrafiltration (cut-off 10’000 Da) and lyophilization resulted in the 
heparin-PDMS-heparin (4.9 mg (0.33 µmol)). 
Characterization: NMR spectroscopy in a 1:1 mixture of D2O and acetone-C6 
suggested the coexistence of PDMS and a residue of the sugar. It could not be 
evaluated if the product still contained heparin, its decomposition product or other 
impurities. 
 
6.1.3 Synthesis of heparin-PDMS by DCC/DMAP method 
 
Heparin-PDMS was synthesized using dicyclohexyl carbodiimide (DCC) as 
coupling agent and 4-dimethylaminopyridine (DMAP) as a base. The amine 
group of diaminopropyl functionalized poly(dimethyl siloxane) (PDMS-(C3H6-
NH2)2) forms a peptide bond to the carboxylic acid moieties of iduronic acid 
moieties of heparin. 0.5 g heparin were dissolved in 50 mL formamide and 0.25 g 
PDMS-(C3H6-NH2)2 (0.5 eq), were dissolved in 50 mL DMF. DCC (1 eq) and 
DMAP (1 eq) were added to the heparin solution followed by stirring for 10 min 
and addition of the PDMS-(C3H6-NH2)2 solution. The reaction mixture was stirred 
at 50°C for 12h under nitrogen atmosphere. To remov e unreacted heparin, the 
solution was diluted with water and set to ultrafiltration, cutoff 10’000 Da. After 
ultrafiltration, the product was washed with cyclohexane and dried in vacuo. 
 
6.1.4 Fluorescence labeling of protamine 
 
To bind the succinimidyl ester group of OG488 to an amine group of protamine 
the following reaction was used according to the coupling reaction described by 
Invitrogen, Amine reactive probes, 2005. 5.2 mg of protamine (1eq) was 
dissolved in 0.5 mL of a 0.1M sodium bicarbonate buffer (pH 8.4). 0.5 mg OG488 
(0.83 eq) dissolved in 50 µL DMF were added while stirring. After vortexing, the 
reaction was incubated for 4 hours at room temperature under continuous 
stirring. The product was purified by HPLC chromatography, using a 
LiChrosopher 100, RP-18e (5µm), 250-4.6 column. The product was 
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characterized by MALDI-TOF (PerSeptive Biosystems Voyager-DE Pro, 
Biospectrometry). 
 
6.1.5 Hydrogenation of PB-NH2 to PEE-NH2 
 
Amino end functionalized poly(butadiene) PB-NH2 (MW: 2000 Da) was 
synthesized and kindly donated by the group of Prof. Axel Müller (Universität 
Bayreuth) 81. 
4.2 g of PB-NH2 were dissolved in 100 mL cyclohexane. 0.5 g Pd catalyst on 
carbonate were prepared in a glass vial and activated under H2-atmosphere in 
the autoclave at 100 bar, 70°C for 4h. After coolin g down to RT, the pressure 
chamber was opened and the PB-NH2 solution added to the catalyst. The 
reaction mixture was set under H2 atmosphere at 100 bar 100°C for 12h. Then, 
the reaction mixture was filtered through Millipore syringe filters, cutoff 0.45µm 
and dried in vacuo. 
Yield: 1 g PEE-NH2 
 
6.1.6 Coupling heparin to PEE 
 
46 mg heparin was dissolved in 10 mL H2O. 100 mg PEE was dissolved in 20 mL 
THF. The two solutions were mixed and 10 mg NaBH3 was added. The pH was 
adjusted to 3.5 with HCl and the reaction mixture was stirred under argon 
atmosphere at 50°C for 8h, then purified with prepa rative RP-HPLC. 
Yield: ca. 5 mg heparin-PEE 
 
6.1.7 Preparation of heparin-PEG with triazine method 
 
125 mg Heparin (0.25mmol, ~1mmol carboxylic acid) was mixed with previously 
washed Dowex H+ to obtain the acid. Then it was dissolved in 10 mL H2O, 
followed by addition of acetonitrile. The mixture was stirred for 2 h. 110 µl 
(1mmol) 4-methylmorpholine was added, cooled to 0°C  and stirred shortly. 
90mg (0.5mmol) CDMT, resp. 45 mg (0.25mmol) CMDT was added and the 
reaction mixture was stirred for 1h at RT. 
125 mg (1mmol) amino-PEG50000 was dissolved in 6 mL H2O and added to the 
reaction mixture, followed by stirring for 20h at RT. 
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For purification, the product was ultrafiltrated (cut-off 10’000 Da), until no 
conductivity was measurable in the outflow. 
 
6.1.8 Synthesis of heparin-PEG by degradation and  reductive amination 
 
Nitrous acid degradation 
 
200 mg heparin (MW: 5000Da, 40 µmol) was dissolved in 60 mL H2O in a 100 
mL round flask at RT, followed by addition of 2 mg NaNO3. The pH was adjusted 
to 2.7 using 1M HCl and the solution was stirred for 24h at RT. 
Then NaOH was added until pH 7 was reached. 
Upon ultrafiltration (cut-off 1000 Da), followed by lyophilization, heparin-aldehyde 
was obtained.  
 
Coupling with PEG(5000)-NH2 by reductive amination 
 
20 mg (4 µmol) heparin-aldehyde was dissolved in 100 mL 0.15M NaCl solution. 
100 mg (20 µmol) PEG-NH2 (MW=5000Da) was dissolved in benzene and 
freeze-dried (3x), then added to the heparin-aldehyde. PH was adjusted to 3.5 
using 1M HCl. 
10 mg (0.16 µmol) of cyanoborohydride was added, and the solution was stirred 
for 48h at 50°C. 
After cooling, the solution was ultrafiltrated (cut-off 5000 Da) with H2O. 
Lyophilization led to 100 mg heparin-PEG (2.1 µmol). 
 
6.1.9 Coupling D-glucosamine to the TRUNK via carboxylate 
 
The TRUNK was synthesized by Fmoc SPPS on chlortrityl chloride resin. The 
synthesis was carried out with the same procedure as described in chapter 
6.1.12, except the deprotection step of the resin could be omitted, because 
chlortrityl chloride is free of protecting groups. The TRUNK was cleaved from the 
resin with the addition of 0.5% TFA in DCM (5 mL) and shaking for 2 h. 
After purification in ice-cold isopropyl ether, the reaction mixture was dissolved in 
DMF. 4 equivalents D-glucosamine were dissolved in formamide and added to 
the DMF solution together with HCTU (1 eq) and 0.5 mL DIPEA and shaken for 
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24 h. Then the reaction mixture was poured into ice cold isopropyl ether and 
dried. The residue was analyzed by MALDI-TOF-MS and analytical HPLC: 
The product could be detected by MALDI-TOF-MS, but the amount was too low 
to be detectable by HPLC. 
 
6.1.10 Preparation of D-glucosamine-aldehyde 
 
1 g of D-glucosamine (4.64 mol) was solved in 50 mL water. Then 300 mg 
sodium nitrite was added. HCl was added drop wise, until the pH was set to 2.7. 
The formation of bubbles shows that nitrogen gas developed, which is an 
indication that the reaction started. The solution was gently stirred for 24 h. 
After evaporation of water we found a brown-black residue, which could not be 
detected as aldehyde by IR. 
As a second attempt, we raised the pH back to 7 before removal of the water. 
The yellow residue turned out not to be an aldehyde again. 
To avoid the formation of a Schiff’s base right after the formation of the aldehyde 
with amino-groups of still unreacted D-glucosamine molecules, we used an 
acetylated D-glucosamine to protect the amino groups. The reaction was carried 
out in the same way, but no bubbles formed. IR spectroscopy revealed that no 
reaction took place. For the coupling reaction we took plain D-glucosamine. 
  
6.1.11 Coupling D-glucosamine-aldehyde to the TRUNK via reductive amination 
 
After the last coupling step of the TRUNK synthesis by Fmoc SPPS on Rink 
Amide AM, the N-terminal tryptophane was deprotected with 20% piperidin, 
washed with DMF and isopropanol and dried.  
4 equivalents of D-glucosamine in water were added to the resin with a small 
amount (tip of a spatula) of sodium cyanoborohydride. The reaction solution was 
shaken for 2 h and washed 3 times with water. 
For the cleavage from the resin, a solution of 4.75 mL TFA, 0.125 mL H2O and 
0.125 mL TES were added to the Rink Amide and shaken for 2 h. Then the 
reaction mixture was poured into 40 mL of ice cold isopropyl ether and 
centrifuged. The residue was collected and analyzed by MALDI-TOF-MS and 
analytical HPLC. 
No product could be detected. 
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6.1.12 Synthesis of TRUNK –GluAc by SPPS 
 
The glycopeptide was synthesized with a batch synthesizer (Syro 1 MultiSynTech 
Workstation) on solid phase using Fmoc protection group synthesis. Rink Amide 
AM resin (loading 0.7mmol/g) was used as solid phase and all reactions were 
carried out in DMF as reaction solvent. The synthesis was performed in a 10 mL 
syringe filled with 200 mg resin. The Fmoc protected amino acids were dissolved 
in DMF (0.5 M) and glucuronic acid was dissolved in formamide (0.5M) prior to 
the synthesis. The reaction was carried out according to the protocol in Table 4. 
The Fmoc protection group was cleaved twice for each coupling step using 40% 
piperidin in DMF. HCTU was used as coupling agent and DIPEA, dissolved in 
NMP, as a base. The coupling reaction was executed with 4 equivalents (eq) of 
amino acid, 4 eq of glucuronic acid, 4 eq of HCTU and 12 eq DIPEA relative to 
the resin loading. After each coupling step, the terminal amino group was capped 
by acetylation with a solution of 4 eq acetic anhydride and 5 eq of DIPEA in DMF. 
The product was alternatingly washed three times with DMF respectively 
isopropanol and subsequently dried over night.  
 
Step Reagent/Solvent Repetitions Time Description 
1 40% Piperidin/DMF 1 5 min Fmoc deprotection 
2 40% Piperidin/DMF 1 10 min Fmoc deprotection 
3 DMF, 4eq Fmoc protected 
AA/glucuronic acid 
5 1 min Wash 
4 4 eq HCTU, 12 eq DIPEA 1 60 min Coupling 
5 DMF 2 1 min Wash 
6 4 eq HCTU, 12 eq DIPEA 1 20 min End capping 
7 DMF 3 1 min Wash 
Table 4: Reaction protocol for the Fmoc SPPS of the glycopeptide 
 
Cleavage from Resin 
 
Glycopeptide cleavage from the resin and removal of protection groups was done 
with 95% TFA, 2.5% triethylsilane and 2.5% H2O. The ice cooled cleavage 
mixture was added to the resin and agitated during 120 min. Subsequently, the 
cleavage mixture was precipitated in 40 mL ice cooled diisopropylether and 
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centrifuged for 20 min at 9000 rpm. The supernatant was decanted and the 
precipitated glycopeptide redispersed in another 40 mL of diisopropylether. After 
another centrifugation (20 min, 9000 rpm) the residual crude product was dried 
over night in a desiccator. 
 
Preparative Purification (Reverse Phase HPLC) 
 
All HPLC purifications were carried out on a Shimadzu Prominence 20A HPLC-
System. 
In the following, buffer A denotes 0.1% TFA in bidistilled H2O, buffer B stands for 
acetonitrile (ACN). 
The glycopeptide was purified on a Shimadzu Prominence HPLC. The 
glycopeptide crude material was dissolved in 2 mL DMF, diluted with H2O (0.1% 
TFA) to a final volume of 20 mL, then ACN was added until the glycopeptide was 
completely dissolved. The solution was filtered through a 0.45 µm PTFE syringe 
filter. The solution was pumped into a RP-18e (5 µm), 250-10 column at a flow 
rate of 3 mL/min by a sample pump. After 5 minutes of column equilibration on 
20% buffer B the gradient to 95% buffer B was applied. 
The product was fractionated when the absorption exceeded 200 mAU at 280 nm 
and the collected fractions were analyzed qualitatively for mass by MALDI-TOF 
MS and quantitatively for purity by analytical HPLC. Fractions with more than 50 
area% product peak were combined and diluted 1:1 with 2% AcOH in H2O and 
reapplied to the preparative RP-HPLC column, this time with 2% AcOH in the 
aqueous solvent A. The fractionation conditions in the second run and the 
analysis of the collected fractions were performed according to the first 
purification run; fractions with more than 95% product peak were combined. 
  
Product Characterization 
 
Purity analysis and quantification of the sample was determined by analytical 
HPLC (RP-18e(5µm), 250-4.6) and calculated by the ration of product peak 
integral to the overall integral of the elution diagram.  
 
Elimination of Counter Ions 
 
TFA- - counter ions were eliminated by the second preparative RP-HPLC step 
carried out with 2% acetic acid in the aqueous phase. AcO- in turn, as a counter 
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ion of the cationic peptides, was eliminated by repeated addition of ammonia 
prior to lyophilisation according to the following protocol. 
1. Addition of ammonia to pH 11 and lyophilization on a Heto Maxi Dry Lyo 
2.  Dissolution in 40 mL 30% ACN in bidistilled water, addition of ammonia to 
pH 11 and lyophilization 
3.  Repetition of step 2 
4. Dissolution in 40 mL 30% ACN in bidistilled H2O and lyophilization 
5. 2 repetitions of step 4 
 
6.2 Characterization methods 
 
6.2.1 Light scattering 
 
Dynamic light scattering (DLS) and static light scattering (SLS) measurements 
give the opportunity to evaluate if the aggregates were vesicles. When an 
incident beam of electromagnetic radiation interacts with a molecule and changes 
its direction without loosing energy, elastic scattering takes place. 
Particles in solution are in constant random movement due to thermal collisions 
(Brownian motion). This results in fluctuations in the scattered intensity, which is 
measured in the case of dynamic light scattering. DLS renders information about 
the dynamics of a system, such as translational diffusion coefficient (Dapp) from 
which the hydrodynamic radius (Rh) of spheres can be calculated using the 
Stokes-Einstein equation: 
 
Rh = kBT/6πηD0 
 
kB   =  Botzmann constant 
T   =  absolute temperature 
η   = solvent viscosity 
D0 =  diffusion coefficient at infinite dilution, obtained by extrapolation to zero 
concentration 
 
In SLS, the excess intensity of the solution containing the particles is compared 
to the scattered intensity of the pure solvent. The photons collected by the 
CHAPTER 6  METHODS
 
 
 85 
detector are averaged over a certain time. SLS provides information about weight 
average molecular weights and radii of gyration. 
Dynamic light scattering was performed using an ALV DLS/SLS-5022 F compact 
goniometer system (ALV-Laser Vertriebs GmbH, Langen/D) equipped with an 
ALD/CGS-8F goniometer, an ALV-5000-EPP multiple tau digital Correlator, ALV 
Correlator software 3.0 and a 1145P-3083 HeNe-laser (JDS Uniphase, 
Manteca/CA, 22mW, 622nm) at scattering angles between 30° and 150°. Quartz 
cuvettes were obtained from Hellma (Hellma, Müllheim/D). 
Prior to measurement, aqueous solutions were extruded through a 0.8µm 
Millipore filter to remove impurities. Measurements were typically performed with 
five dilutions per sample and at angular steps of 10° between 30° and 150°. 
 
6.2.2 Transmission electron mictroscopy (TEM) 
 
TEM images were taken on a Philipps EM 400 (Philips Electronics, 
Eindhoven/NL) operated at 80 kV equipped with a Megaview III charge-coupled 
device camera (CCD) and controlled with Morgagni 268D control and image 
acquisition software. 
2 µL sample was absorbed on a glow discharged, parlodion coated, 300 mesh 
copper grid and incubated for 5 min, before the droplet was blotted away. 
 
6.2.3 MALDI-TOF-MS 
 
MALDI-TOF-MS (matrix assisted laser desorption ionization – time of flight –
mass spectroscopy) was accomplished on a PerSeptive Biosystems Voyager-DE 
Pro (Biospectrometry) spectrometer; 0.8 µl of sample solution (c ∼ 1 mg/mL) was 
applied to a gold sample plate and mixed with 0.8 µl of matrix solution (1 mg/mL 
α-cyano-4-hydrocinnamic acid (dissolved in a 1:1 mixture of ACN and H2O (0.1% 
TFA)). Spectra were taken in reflector mode with positive polarity and a manual 
acquisition control. The grid voltage was set to 75%. 400 to 600 laser shots were 
averaged. 
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6.2.4 Antifactor Xa activity test 
 
The antifactor Xa activity tests were carried out on a coagulation analyzer STA-R 
from Stago. 
Human blood was centrifuged for 10 min at 6000 g to sediment thrombocytes. 
The plasma overstand was used as solvent and antithrombin III source. The 
highest measurable concentration of LMWH for the antifactor Xa activity test is 
1.5 IU LMWH, which corresponds to ca. 15 µg/mL. To obtain solutions of 15 
µg/mL, stock solutions were prepared in water. For the coupled heparin samples, 
the assumed actual heparin concentration was calculated. 1.5 µl of each was 
added to 1 mL plasma.  
The samples were heated to 37°C and vortexed. 50 µl plasma solution was 
pipetted, then 125 µl chromogenic substrate (S-2222: N-benzoyl-L-isoleucyl-L-
glutamyl-glycyl-L-arginine-p-nitroaniline hydrochloride and its methyl ester, conc. 
2 mg/mL) were added. The mixture was incubated at 37°C for 4 min. After 
transfer to the measuring block, 125 µl factor Xa solution (2 mg/mL) was added 
and absorbance of p-nitroanilin was measured after 20 s and 60 s. 
Factor Xa decouples p-nitroanilin from the tripeptide, which then absorbs at a 
wavelength of 405 nm. Upon inhibition of Xa, the increase of the detachment of 
p-nitroanilin slows down, meaning that the absorbance increase slows down with 
time. Comparing the absorbances with heparin calibration curves, the amount of 
active heparin and heparin derivatives in solution could be determined. 
 
6.2.5 Gel electrophoresis 
 
1g agarose was dissolved in100 ml 0.04 M barium acetate. The pH was adjusted 
to 5.8 with acetic acid and the solution was heated in the microwave oven until 
agarose had dissolved. Then the solution was poured into a holder, an eight hole 
comb was placed inside and cooled down to RT. 
Solutions of approx. 0.5 mg/ml were placed into the holes together with loading 
buffer. 
As running buffer 0.05 M 1,2-diaminopropane (1.853g/500 ml), pH 9 adjusted 
with acetic acid, was used.  
The current was set to 50 mA for 150 min. Then the gel was set into a 0.2% 
cetylpyridium chloride and shaken over night. After rinsing with water, the gel was 
placed into a fridge box with 100 mL 0.2% toluidine blue solution in buffer (500 
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mL EtOH, 490 mL H2O, 10 mL acetic acid) 37. The same buffer – without toluidin 
blue - was used to destain until the sample stains were visible.  
 
6.2.6 Fourier transform infrared spectroscopy 
 
FT-IR spectra were acquired on a Shimadzu FTIR8400S spectrometer by placing 
a small amount (tip of a spatula) dry sample on the sapphire holder of the 
spectrometer. 
  
6.2.7 NMR 
 
NMR spectra were acquired on a Varian Unity 400 NMR spectrometer; the 
spectrometer was operated at 400 MHz with a sweep width of 8278.146 Hz and 
22° pulse width of 2.96 µs. For water soluble compo unds, D2O was used as 
solvent; in case of heparin-containing amphiphiles D2O was mixed with acetone-
D6 in a 1:1 ratio. In case of hydrophobic substances, CDCl3 was used as solvent. 
Quantification was carried out by using a chemical shift table from Mulloy et al.94 
I H1 5.22 
I H2 4.35 
I H3 4.20 
I H4 4.10 
I H5 4.81 
A H1 5.39 
A H2 3.29 
A H3 3.67 
A H4 3.77 
A H5 4.03 
A H6 pro-(S) 4.39 
A H6 pro-(R) 4.27 
A NH 7.82 
Table 5: 1H chemical shifts in ppm. I = iduronate residue; A = glucosamine residue 
 
The anomeric protons at the iduronate and the glucosamine residue (I=5.22, 
A=5.39) were taken as indications to find heparin and to quantify the sugars. 
They were chosen because they don’t overlap with other signals. 
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6.2.8 Fluorescence Imaging by Confocal Microscopy 
 
Confocal laser scanning microscopy (LSM) images were taken with a ZEISS 
LSM 510 META with FCS ConfoCor 2 confocal microscope, equipped with a 
100x water immersion objective. An argon laser (488 nm) was used to excite OG 
488 and a HeNe laser (633 nm) to excite BODIPY. To detect the fluorescence 
emission of OG 488 a band-pass 530-600 nm was inserted and to detect the 
BODIPY a low-pass > 650 nm was used. 
 
6.2.9 FCS/FCCS measurement 
 
Fluorescence correlation spectroscopy (FCS) and fluorescence cross correlation 
spectroscopy (FCCS) measurements were accomplished on a ZEISS LSM 510 
META/Confocor2 microscope equipped with different laser lines. The filter sets 
for λ = 488 nm and 633 nm were chosen to excite the OG488 and BODIPY 633 
labelled samples.  
 
Figure 60: Schematic diagram of the beam path of the dual-laser cross-correlation setup 95 
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FCS is measured in a volume smaller than ¼ femtoliter. The number of detected 
molecules fluctuates due to thermodynamic fluctuations, similar to DLS. But in 
contrary to scattered light, the measured intensity reflects the varying number of 
excited molecules. The measured signal can be described as constant mean 
intensity < I > and a fluctuating contribution δ I (t). These fluctuations δ I (t) carry 
the information we are interested in. From comparing the signal with each other 
(FCS) or with another signal (FCCS), a correlation function can be calculated: 
 
2
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The thus obtained function can be fitted to a biophysical model, being - for the 
simplest case - a single dilute species: 
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N = number of molecules 
τd = diffusion time of molecule 
ω  =  ωz/ ωxy, aspect ratio of det. volume 
 
 
The resulting fitted curve gives the information about the concentration and the 
diffusion time of the molecules or particles in the sample and thus their size. 
 
6.2.10 EPR measurements 
 
The basic physical concept of EPR is analogous to NMR, but instead of nuclei 
spins, electron spins are excited. 
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The electron’s magnetic moment aligns itself either parallel or antiparallel to an 
external magnetic field, with a specific energy for each alignment. The energy 
levels split proportionally to the magnetic field’s strength. 
An unpaired electron can change between the two energy levels by either 
absorbing or emitting electromagnetic radiation. Due to Maxwell-Boltzmann 
distribution, there are more electrons in the lower state, therefore there will be a 
total net absorption, which is measured. EPR spectra are usually presented as 
first derivatives of the absorbance. 
If an atom with an unpaired electron has a nuclear spin, this electron will be 
affected by the nucleus’ magnetic moment. This leads to the splitting of the EPR 
resonance signal, and is called hyperfine coupling, comparable to J-coupling in 
NMR. 
 
Electron paramagnetic resonance (EPR) spectra were recorded with a CW 
Bruker ElexSys500 X-band CW spectrometer, equipped with a helium 
temperature control system (ER4112HV), to which the wave-guide resonance 
cavity was attached. Microwave power was adjusted at levels below the 
saturation condition: for copper this was at 2 mW for high field measurements 
and at 10 mW for low field measurements, while for Gd this was at 6mW. The 
modulation frequency was 100 kHz and the modulation amplitude was 0.5 mT; 
other spectral parameters were adjusted for each spectrum individually. 15 
spectra were acquired to optimize the signal-to-noise ratio, and 3rd-order 
polynomial averaging was used for subsequent noise reduction.  
Cu samples were measured at 125K and 77K, while Gd samples were measured 
in a temperature interval of 270K - 125K. The intensity of each spectrum was 
calculated via double integral of D1EPR. Gaussian line shapes were considered 
with the line-width adjusted for each spectrum. 
The spectral parameters were obtained with the SIMFONIA software package 
(Bruker Instruments Inc., Manning Park, Billerica, MA), where co-axial g and 
hyperfine tensors were assumed. The g-values were referenced to 
diphenylpicryhydrazyl (DPPH) (g = 2.0036) as an external standard. 
 
6.2.11 MRI measurements 
 
Eppendorff test tubes filled with aqueous solutions (concentrations of 0.01, 0.1, 
0.2, 0.3, 0.4, 0.5, 1 mMol) of heparin-PEG complexed with GdCl3 and GdPO4 
with multiple concentration ratios between polymer and Gd3+ or GdPO4 salt (5:1, 
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2:1, 1:1) were scanned on a human whole-body 1.5T imaging scanner (Avanto, 
Siemens Medical Solutions, Erlangen, Germany) in order to evaluate the R1 and 
R2 relaxation rates. The samples were set into a holder for Eppendorff vials. For 
R1 evaluation, conventional 2D spin echo sequences with multiple TR values of 
100, 200, 300, 400, 500, 750, 1000, 2000 ms, a TE of 11 ms, a resolution of 
0.47x0.47x5 mm3, matrix size 256x104, slice thickness of 5 mm and a bandwidth 
of 130Hz/px were used; for R2 measurements a multi-contrast 2D spin echo 
sequence with same resolution, TR 4000ms and 32 contrast with echo spacing of 
18ms was acquired. 
 
Image processing and parameter fitting 
 
The images were exported to a computer and evaluated using Matlab (The 
Mathworks, Natick, MA). The extrapolation of the relaxation rates was obtained 
through nonlinear least-squares fitting of the mean signal over ROIs placed in the 
tubes. The fitting function for the R1 estimation was the standard T1-weighted 
spin echo function: 
 ( )1 1( / 2)1 2 R TR TE R TRS e eα − − −= − + , 
the fitting function for R2 estimation was a monoexponential function: 
 
2R TES eα −=  
The linear regression coefficient of relaxation rates at different concentrations 
was calculated in order to obtain the contrast agent relaxivity. 
 
6.2.12 SEM/EDX 
 
SEM images were acquired on a Philips XL 30 ESEM (Philips Electron Optics, 
The Netherlands) scanning electron microscope, equipped with a dedicated 
gaseous secondary electron detector (GSED) that allows true secondary electron 
imaging at full SEM resolution in gas or water vapor. An embedded module 
allows energy dispersive X-ray microanalysis (EDX). 
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6.3 Sample preparations 
 
6.3.1 PEG-PPS GUV’s with heparin-PDMS for fluorescence imaging 
 
11.8 mg PEG-PPS were dissolved in 1.5 mL chloroform (2.73 mM) and 1.8 mg of 
heparin-PDMS was dissolved in 0.5 mL water (0.36 mM). Three emulsions with 
different heparin-PDMS to PEG-PPS ratios were prepared (Table 6). As a control 
experiment a sample with pure 0.46 mM PEG-PPS solution was prepared (table, 
sample 4). 1 µL of 6.7 mM BODIPY (6.7 nmole) dissolved in DMSO was added 
to all solutions. Accordingly the solutions were vortexed for some seconds and 
then stirred for 3 hours. To form immobilized giant vesicles with diameters 
between 10-100 µm, glass fibers were coated with a thin polymer film by dipping 
them into the polymer solutions76. The fibers were dried in a vacuum drier for 20 
hours (RT, 1 mbar). For imaging the dry fibers were resolved in 0.5 mL water. To 
verify the binding 3 µL of 2 mM labeled protamine (6 nmole) were added. 
 
Sample VP-P (µL) VH-P 
(µL) 
nP-P 
(nmole) 
VP-P (nmole) nP-P /nH-P 
1 50 50 137 18 7 
2 150 40 410 14 30 
3 100 10 273 3.6 76 
4 300 - 137 - - 
Table 6: Ratios between PEG-PPS (P-P) and heparin-PDMS (H-P) 
 
6.3.2 Preparation of PEG-PPS samples with heparin-PDMS for fluorescence 
imaging and FCS/FCCS 
 
PEG-b-PPS polymer, dissolved in chloroform, was mixed with heparin-PDMS in 
water at different ratios. The solutions were shaken until an emulsion formed. 
Thin glass fibers were dipped into the solution and dried over night in an oven. 
The glass fibers were rehydrated with water containing BODOIPY 630. For FCS 
and FCCS measurements, the samples were dried without glass fibers and 
rehydrated. After dissolution, the samples were filtered six times through a 0.2 
µm Millipore filter before the measurements. 
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6.3.3 Preparation of glycopeptide aggregates 
 
The glycopeptide was dissolved in 2 mL EtOH at concentrations of 0.5 to 2 
mg/mL. Subsequently, the mixture was dialyzed (CE 1000 Da cutoff) three times 
against 1 L of bidistilled H2O. 
 
6.3.4 Dynamic Light Scattering (DLS) of the glycopeptide 
 
An ethanol solution of the glycopeptide was filtered through a 0.8µl Millipore filter 
and dialyzed against 20%EtOH in H2O, 10% EtOH in H2O, and pure H2O. The 
solutions were subjected to DLS using an ALV/CGS-8F platform based 
goniometer system equipped with an ALV/-5000/E correlator and an argon-ion 
laser with a wavelength of 633 nm (35 mW). Correlation functions were fitted by 
the cumulant function. Concentration dependencies and multiple scattering 
effects were minimized by extrapolation of the concentration and the angle to 0. 
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8 ANNEX 
8.1 Abbreviations 
 
ACN   acetonitrile 
AFM   atomic force microscopy 
ATIII   antithrombin III 
BODIPY  dipyrromethene boron difluoride 
CA   contrast agent 
CLSM   confocal laser scanning microscopy 
CMDT   2-chloro-4,6-dimethoxy-1,3,5-triazine 
Da   Dalton 
DCC   dicyclohexyl carbodiimide 
DCM   dichloro methane 
DIPEA  N,N-diisoprpylethylamine 
DLS   dynamic light scattering 
DMAP   4-dimethylaminopyridine 
DMF   dimethyl formamide 
DMSO  dimethyl sulfoxide  
DNA   deoxyribonucleic acid 
EDX   energy dispersive X-ray microanalysis 
EPR   electron paramagnetic resonance spectroscopy 
EtOH   ethanol 
FCS   fluorescence correlation spectroscopy 
FCCS   fluorescence cross correlation spectroscopy 
FGF   fibroblast growth factor 
GAG   glycosaminoglycan 
GluAc   D-glucuronic acid 
GUV giant unilamellar vesicles 
h hour(s) 
HCTU O-(6-chlorbenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium-
hexafluorophophate 
HIT   heparin-induced thrombocytopenia 
HPLC   high performance liquid chromatography 
IR   infrared spectroscopy 
ISA   ionic self-assembly 
L (DL)   leucine (D-leucine) 
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LamB   Maltoporin 
LMWH  low molecular wight heparin 
MALDI-TOF-MS matrix assisted laser desorption absorption-time of flight-
mass spectroscopy 
M mol/L 
min   minute(s) 
MRI   magnetic resonance imaging 
NMR   nuclear magnetic resonance spectroscopy 
OG   Oregon green 
OmpF   E. coli outer membrane porin 
OTf   trifluoromethane sulfonate (= triflate) 
PDMS   poly(dimethyl siloxane) 
PEE   poly(ethyl ethylene) 
PEG   poly(ethylene glycol) 
PMOXA  poly(methyl oxazoline) 
ppm   parts per million 
PPS   poly(propylene sulfide) 
Rg   radius of gyration 
Rh   hydrodynamic radius 
RNA   ribonucleic acid 
RP   reverse phase 
RT   room temperature 
SEM   scanning electron microscopy 
SLS   static light scattering 
SPPS   solid phase peptide synthesis 
Tg   glass transition temperature 
TEM   transmission electron microscopy 
TES   triethylsilane 
TFA   trifluoracetic acid 
UF   ultra filtration 
UFH   unfractionated heparin 
UV   ultra violet 
W   tryptophane 
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8.2 Chemicals 
 
- Acetic acid, glacial, 100%, VWR ProLabo 84 528.290 
- Acetic anhydride, purum, Synopharm 017700 
- Acetone-D6, Fluka, puriss., 666-52-4 
- Acetonitrile, HPLC grade ≥99.9%, Fisher Chemicals A/0626/17 
-  α-Cyano-4-hydrocinnamic acid (CCA), 97%, Aldrich 14,550-5 
- Barium acetate, Fluka, puriss., 534-80-6 
- BODIPY® 630-650 methyl bromide (BODIPY), Invitrogen 
- 2-Chloro-4,6-dimethoxy-1,3,5-triazine (CDMT), Aldrich 3140-73-6 
- Chloroform, Sigma-Aldrich, 98.8%, 67-66-3 
- Cyclohexane, Fluka, purum, 110-82-7 
- D2O, Cambridge isotope laboratories Inc. 7789-20-0 
- 1,2-Diaminopropane, Fluka, puriss., 78-90-0 
- Dichloromethan, rein, Schweizerhall 81830-156 
- Dicyclohexylcarbodiimide (DCC), Fluka, puriss., 538-75-0 
- 4-dimethylaminopyridine (DMAP), Aldirch, 99%, 1122-58-3 
- dimethyl formamide (DMF), Fluka, puriss. 68-12-2 
- D-glucuronic acid, 99%, Sigma-Aldrich 6556-12-3 
- D-glucosamine, 99%, Sigma-Aldrich 66-84-2 
- Diisopropyl ether, puriss. p.a. ≥ 98%, Fluka 38279 
- Ethanol, 96% EP, Schweizerhall 82352-102 
- Fmoc-D-Leu-OH, ≥98% (HPLC), Novabiochem 04-13-1025 
- Fmoc-Trp(Boc)-OH, ≥(HPLC), Novabiochem 04-12-1103 
- Formamide, puriss, Fluka 75-12-7 
- GdCl3 * 6 H2O provided by Novartis 
- hexane, Fluka, puriss., 110-54-3 
- Low molecular weight heparin (LMWH) Na+ salt, Sigma-Aldirch 9041-08-1 
- 4-Methyl-morpholine (NMM), Fluka, 109-02-4 
- 1-Methyl-2-pyrrolidinone (NMP), ≥99.5% (GC), Fluka 69116 
- N-acetyl-D-glucosamine 99%, Sigma Aldrich 7512-17-6 
- N,N-Diisoprpylethylamine (DIPEA), 99%, Aldrich D12,580-6 
- N,N-Dimethylformamide (DMF), purum, ≥ 99.9% (GC), JT. Baker 7032 
- (O-(6-Chlorbenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium-
hexafluorophophate) (HCTU), 99.7%, Iris Biotech GmbH 330645879 
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- Oregon green® 488 dye, carboxylic acid, succinimidyl ester (OG488), 
Invitrogen, 198139-51-4  
- Pd CO3, Fluka, puriss., Fluka, 10% 
- Poly(dimethylsiloxane) aminopropyl terminated (PDMS-(C3H6-NH2)2), 
ABCR 106214-84-0 
- Poly-L-lysine MW 20’000-30’000 Da, Fluka 81333 
- Piperidine, purum, ≥ 96% (GC), Fluka 80642 
- Pyridin, ReagentPlus, ≥99.0% (GC), Fluka 320498 
-  Rink Amide AM resin (200-400 mesh), Novabiochem 01-64-0038 
- sodium cyanoborohydride NaBH3CN, Fluka 25895-60-7 
- sodium phosphate Na2HPO4, Sigma-Aldrich, 99%, 7558-79-4  
- Toluidine blue, Fluka, 6586-04-5 
- Triethylsilane (TES), 97%, Fluka 90550 
- Trifluoroacetic acid (TFA), ≥ 98%, Fluka 91700 
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8.3 History of heparin 
 
Heparin was discovered in 1916 at Johns Hopkins University by John McLean, a 
second-year medicine student in William H. Howell’s laboratory. He was isolating 
phosphatides from heart and liver tissues using organic solvents, and noticed 
anticoagulant activity of his extracts. He misnamed the active compound hepar 
(liver) phosphatide, until Howell recognized that the compound had no phosphate 
but was a polysaccharide and renamed it heparin96. During the 1920s, Howell 
kept investigating heparin and isolated the polysaccharide by extraction with 
water. 
In the early twentieth century, hirudin from leech salivary glands was the most 
widely used anticoagulant, mainly for indirect blood transfusion, but purification of 
this inhibitor was expensive and the substance was unsafe for patients. Heparin, 
being an endogenous mammalian substance, represented a promising 
coagulation regulator. Howell convinced the pharmaceutical company Hynson, 
Westcott and Dunning to bring heparin on the market commercially, but as no 
efforts for further development of the isolation protocol was made, the 
commercial profit remained unsatisfactory97.  
It only got practically applied from the early 1930, when a team led by Dr. Charles 
H. Best (1899-1978) at Connaught developed a method to establish a supply that 
was pure, plentiful, inexpensive and safe for human use.  
Connaught, the Department of Physiology at Toronto University, is well known 
from its involvement in insulin development, but less is known about its role on 
heparin’s history. Until 1928, heparin was only available from dog liver in small 
amounts. Furthermore, it was expensive and toxic. 
After encouraging early work, Dr. Gordon Murray 
(1896-1976), a prominent surgeon at Toronto 
General Hospital, joined Best’s team to conduct 
experimental surgery using heparin. The first choice 
for a cheaper heparin source was beef liver, readily 
available at slaughterhouses, but as the pet food 
industry began to grow, the prices were rising and 
another source had to be found. Beef lung and 
intestines turned out to be also good resources of 
heparin, the latter cheaper and more plentiful as 
there was no use for it as pet food. The extraction of 
 
Figure 61: Dr. Charles Best 
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heparin proved to be rather unpleasant considering that the method involved 
letting these tissues “autolyze”, or spoil, before preparation. The next challenge 
was to study the still mysterious chemistry of heparin. Between 1933 and 1936, 
purification and crystallization of heparin into a standardized dry form that could 
be administered in a salt solution was achieved. After insulin, heparin became 
the second product from Connaught to be recognized as an international 
biological standard. 
Meanwhile in Sweden, Sune Bergstrom, winner of the Nobel Prize for research 
on prostaglandins, started to investigate the structure of heparin and correctly 
identified glucosamine as a sugar component, while working as a student with 
Eric Jorpes in Sweden. Jorpes and later Arthur Charles established that heparin 
contained a high content of sulfo-groups. In 1950 Jorpes also determined that the 
glucosamine residue in heparin was primarily N-sulfonated. Melville L. Wolfrom 
initially identified the uronic acid residue as D-glucuronic acid in 1946. But it was 
not until 1962, that L-iduronic acid was found and 1968 until it was identified as 
major uronic acid residue in heparin. 
At Connaught in the 1930’s, Murray conducted experimental surgery with various 
animals using this new potent heparin product. After discovering that heparin 
definitely cleared up internal blood clots, and also seemed useful for many other 
dangerous operations where blood coagulated quickly, the next step was to try 
heparin on human patients under less predictable conditions, which was done 
first in May 1935 and continued by hundreds of complex surgical cases during 
which Connaught's heparin played an essential and often dramatic life-saving 
role. 
By 1937 it was proven that Connaught's heparin was a safe, easily available and 
effective blood anticoagulant.  Best's heparin team had opened the door to organ 
transplantations and open heart surgery, as well as the development of an 
artificial kidney, pioneered by Murray. Connaught continued to prepare heparin 
and worked to increase its potency and reduce the price. By 1951, Drs. Edith 
Taylor and Peter Moloney were successful and received a patent for their 
improved methods of heparin production98. Ironically, this work made heparin 
more easily produced elsewhere. Thus, by the early 1950s, Connaught had 
stopped producing this crucial life-saving product that it had pioneered99. 
Despite widely spread medical use of heparin after the second world war, the 
molecular mechanism by which heparin inhibits blood clotting factors was not 
determined until the early 1970s, almost thirty years after completion of the work 
by the Toronto team. 
  
 
